Toxoplasma gondii antigens, the preparation thereof and the use thereof

Abstract

The present invention relates to the identification of Toxoplasma gondii antigens and the preparation thereof by genetic engineering. A cDNA expression gene bank of this parasite was prepared. Recombinant clones which are of diagnostic interest were identified using a high-titer rabbit anti-Toxoplasma gondii serum, and isolated.

Description

The present invention relates to the identification of Toxoplasma gondii antigens and the preparation thereof by genetic engineering. A cDNA expression gene bank of this parasite was prepared. Recombinant clones which are of diagnostic interest were identified using a high-titer rabbit anti-Toxoplasma gondii serum, and isolated.

Toxoplasma gondii (T. gondii) is a obligatory intra-cellular single-cell parasite which is categorized as a coccidium. The parasite has a relatively wide range of hosts and can, in addition to very many mammals, also infect man. In the latter case there are two forms which differ from each other physiologically: "tachyzoites" reproduce asexually in a number of different cell types. This form is found exclusively in the acute stage of the infection. "Bradyzoites", in contrast, persist in cells of the cardiac and skeletal muscles and in cells of the central nervous system in encapsulated form and are responsible for a persistent immunity to reinfection. It is estimated that globally there are 500 million people who are chronically infected by T. gondii.

In healthy adults, a T. gondii infection normally has no symptoms with the exception of a slight swelling of the lymph nodes. During pregnancy and in immunosuppressed patients, however, an infection with this parasite may present particular problems. Thus there is the risk of an intra-uterine transfer of these parasites in pregnant women who have not acquired a protection from T. gondii by immunity. This leads to the infection of the fetus and may result in deformities of the child or the expulsion of the fetus.

Immunosuppressed patients frequently acquire an acute T. gondii infection as a result of the reactivation of enzysted "bradyzoites". In most cases this leads to cerebral toxoplasmosis (encephalitis), which may, under certain circumstances, be lethal. In addition to cerebral toxoplasmosis, T. gondii has also been mentioned as causative agent of eye diseases (chorioretinitis). These cases, too, are infections which can be blamed on a reactivation of "bradyzoites".

The clinical picture of toxoplasmosis often causes difficulties concerning differential diagnosis to the clinician so that the support by laboratory analyses in establishing the diagnosis is sought. The detection of antibodies and the determination of the titer or of the dynamics of the titer have therefore become essential tools for diagnosing toxoplasmosis. Methods for determining toxoplasma-specific immunoglobulins of the G and M class, such as indirect immunofluorescence (IF), complement fixation reaction (CF), indirect hemagglutination (IHA), latex agglutination (LA) and enzyme-linked immunoassay (ELISA) are very common in the field of serodiagnosis but often have faults. For example these test methods vary very greatly as regard specificity and sensitivity. These differences are primarily caused by the preparation of the antigen which is used for the serological test. In most cases total cell antigen which contains a high proportion of unspecific cell components and is held responsible for the occurrence of false positive test results, is prepared. In addition, obtaining the antigens from infected mice holds the risk of infection for the person working in the laboratory.

In view of the specificity and sensitivity of a diagnostic of this type, it would thus be desirable to employ defined immunoreactive antigens which should additionally make it possible to distinguish between IgG- and IgM-specific anti-T. gondii antibodies.

A number of antigens of diagnostic interest have been described for T. gondii in the literature. For example Hughes describes in a review (Curr. Top. Microbiol. (1985), 120: 105-139) four major antigens which are potentially suitable for detecting anti-T. gondii antibodies of the IgG class, having molecular weights of 45, 32, 27 and 21 kilodalton (kD). Handman et al. (Immunol. (1980), 40: 579-588) and Potasman et al. (J. Infect. Diseases (1986), 154: 650-657) analyzed sera taken throughout the course of the disease of acutely infected T. gondii patients using Western blots and demonstrated that a 35 kD membrane antigen reacts with IgG antibody at a very early stage. Decoster et al. (Clinic. Exper. Immunol. (1988), 73: 376-382) describe four antigens of diagnostic interest, which, in contrast to the 35 kD antigen, can be isolated from the culture medium and have been termed "excreted-secreted antigens" (ES antigens) and which have molecular weights of 105, 97, 66 and 28.5 kD. IgG antibodies which react with antigens of 105, 97 and 28.5 kD seem to be good markers for a chronic toxoplasmosis. Similarly to the 35 kD antigen, the 97 kD antigen and the 66 kD antigen are recognized at a very early stage by IgM antibodies of acutely infected patients. It has to be pointed out that these antigens have not been sufficiently characterized by giving a molecular weight after electrophoretic fractionation because there usually are several proteins within one molecular weight range.

A 6 kD antigen is a further marker for acute toxoplasmosis (Ehrlich et al., (1983), Infect. Immun. 41: 683-690). In IgM Western blots, this antigen reacts relatively strongly. To date there are only very few data which might reveal the nature of this antigen.

Only very few T. gondii antigens have been biochemically characterized so far. The main surface protein P30 is an exception. This antigen is a glycoprotein which is anchored in the membrane via a glycolipid (Nagel et al., (1989), J. Biol. Chem. 264: 5569-5576). The diagnostic importance of this antigen is controversial since P30 also reacts with unspecific antibodies of the IgG class (Potasman et al., (1986), J. Clin. Microbiol. 24: 1050-1054).

The isolation and purification of individual antigens for the use in serodiagnosis often involves a considerable amount of work. Both the molecular weight data and the classification of the immunoreactivity of an antigen can substantially differ from case to case in conventionally purified antigen. Cloning and expressing such antigens and investigating the structure of the corresponding genes might not only improve the yield of purified antigen but should also contribute to the serological characterization and therefore to the investigation of the diagnostic relevance of the antigen. So far the structure of the genes of two immunologically interesting T. gondii antigens has been investigated. The complete nucleotide sequences of these antigens, which are P30 (Burg et al., (1988), J. Immunol. 141: 3584-3591) and a 28 kD antigen (Prince et al., (1989), Mol. Biochem. Parasitol. 34: 3-14), are known.

The object of the present invention is to prepare by genetic engineering defined antigens of T. gondii, which are suitable for diagnosis and prevention. It has been possible to successfully identify suitable T. gondii gene products from a lambda gt11 cDNA expression gene bank using a high-titer rabbit anti-T. gondii serum. Partial nucleic acid sequences, and aminoacid sequences derived therefrom, of 8 clones (F2, F28, F29, F34, F45, F61, F74 and F76) have been determined. All the abovementioned clones react in Western blots with human anti-T. gondii IgG sera. The clones F34, F61 and F76 additionally react with specific antibodies of the IgM class. The partial nucleotide sequences are listed in Tab. 1-8 and, as far as they are apparent, also the translational reading frames (in Tab. 1-6).

F61 (Tab. 1) is assigned to a protein having a molecular weight of 66 kD.

F34 (Tab. 2) belongs to a protein of about 68 kD.

F29 (Tab. 3) belongs to a protein of about 30 kD.

F28 (Tab. 4) belongs to a protein of about 28 kD.

F2 (Tab. 5) belongs to a protein of about 30 kD.

F76 (Tab. 6) belongs to a protein of about 35 kD.

F45 (Tab. 7) belongs to a protein of about 29 kD.

F74 (Tab. 8) belongs to a protein of about 64 kD.

With the aid of the partial sequences mentioned it is readily possible to clone the complete genes for the abovementioned partial sequences.

The partial sequences depicted in the Tables 1, 2 and 6 were accordingly used to complete the coding cDNA regions of the genes belonging thereto. For this purpose, the cDNAs F61, F34 and F76 were radiolabeled and used as probes for screening the cDNA gene bank. The sequence from Table 1, F61, was used to isolate the cDNA of the P66 protein. The sequence from Tab. 2, F34, was used for the isolation of the cDNA of the P68 protein. For the isolation of the cDNA of the P35 protein, the sequence from Tab. 6, F76, was used. Recombinant clones having homologies to these sequences were isolated and characterized structurally by sequencing the inserted T. gondii-specific cDNA regions. The nucleotide sequences of the complete ranges of the structural genes of the P35, P66 and P68 proteins are depicted in the Tables 9-11.

Immunologically reactive partial regions (immunogenic parts) are representatively described for P35, P66 and P68 in the Examples 6 and 7. Other immunogenic protein regions are tested or determined in an analogous way.

The invention therefore relates to

(a) the isolated inserted DNA sequences of the abovementioned clones, including the transcription products thereof and the remaining sequences to complete the particular structural genes, (b) DNA structures and vectors which contain, completely or in part, these sequences, (c) prokaryotic or eukaryotic cells which have been transformed with DNA of this type, (d) the polypeptides expressed by transformed cells of this type, or immunogenic parts thereof including the use thereof for diagnosis and therapy or prevention, (e) the amino-acid sequences (AS) belonging thereto, (f) antibodies against the polypeptides under (d), including the use thereof for the diagnosis and therapy or prevention of T. gondii infections, and (g) processes for the preparation by genetic engineering of the polypeptides mentioned under (d) or of immunogenic parts thereof.

The invention is furthermore described in the examples and the claims.

EXAMPLE 1

Construction of a Lambda gt11-cDNA Expression Gene Bank of T. gondii

1) Isolation of poly(A).sup.+ RNA

Confluent Hep-2 cell cultures were infected with T. gondii parasites as described by Braveny et al. (Tropenmed. Parasitologie (1978), 29: 432-434). From day 4 after infection, the trophozoites were harvested by centrifugation of the culture supernatant. The total RNA from about 500 mg of pelleted T. gondii cells (wet weight) was isolated by a modified method of Chomczynski and Sacchi (1987), (Analytical Biochemistry, 162: 156-159) as follows: the cells were lysed in 20 ml of solution D (4M guandinium isothiocyanate, 0.5% sarcosyl, 25 mM sodium citrate pH 7.0, 0.1 M mercaptoethanol) and, after addition of 2 ml of 2 M sodium acetate pH 4.0, 20 ml of phenol (saturated with water) and 4 ml of chloroform, the mixture was shaken vigorously and cooled on ice for 20 min. After a centrifugation step (30 min, 4.degree. C., 15000 g), the RNA was precipitated from the aqueous phase with one volume of isopropanol for one hour at 4.degree. C. and pelleted by subsequent centrifugation (20 min, 4.degree. C., 15000 rpm). The pellet was resuspended in 600 .mu.l of solution D and the RNA was then centrifuged through a 5.7 M CsCl solution (3 ml) (12 h, 35000 rpm, 10.degree. C.). The pellet was resuspended in 500 .mu.l of double-distilled water (free of RNAse) and the RNA was precipitated again with 1/10 volume of sodium acetate and 2 volumes of ethanol for 2 h at -20.degree. C. and pelleted by centrifugation (10 min, 14000 rpm, 4.degree. C. in an Eppendorf centrifuge). Poly(A).sup.+ RNA was enriched via an oligo (dT)-cellulose (Pharmacia) column (0.5 g oligo dT-cellulose in 10 mM tris-HCl pH 7.5, 0.5 M KCl) as follows: LiCl (final concentration 0.5 M) was, after denaturing of the RNA solution (70.degree. C., 10 min), added said and the mixture was run through oligo dT-cellulose column. After the column had been washed with 20 ml of binding buffer (10 mM tris-HCl pH 7.5, 0.5 M KCl), the poly(A).sup.+ RNA was eluted with 10 ml of double-distilled water and precipitated with 1/20 volume of 8 M LiCl and 2.5 volumes of ethanol at -20.degree. C. for 4 h and then pelleted by centrifugation (6000 rpm, 4.degree. C., 30 min), washed in 70% ethanol and dried.

2) cDNA Synthesis

The synthesis of the cDNA was carried out by a modified method of Gubler (U. Gubler, (1988), Nucl. Acids. Res. 16: 2726): after denaturing 5 .mu.g of T. gondii poly(A).sup.+ RNA (5 min, 70.degree. C.), the synthesis of the first DNA strand is carried out in the presence of 50 mM tris-HCl pH 8.3, 75 mM KCl, 50 mM DTT, 15 mM MgCl.sub.2, 0.5 [mM] dNTP, 5 .mu.g of oligo dT primer (Boehringer, Mannheim) and 800 units of reverse transcriptase (BRL) in 50 .mu.l of mixture at 37.degree. C. for 1 h. The reaction is subsequently stopped at 70.degree. C. for 10 min and, after additions of 8 .mu.l of 1 M tris-HCl pH 7.5, 32 .mu.l of 1 M KCl, 1.6 .mu.l of 1 M MgCl.sub.2, 1.6 .mu.l of 1 M DTT, 50 units of E. coli DNA polymerase I (Boehringer, Mannheim), 3.5 units of RNAse H (Boehringer, Mannheim) in 320 .mu.l final volume, the synthesis of the second DNA strand is started. The mixture is incubated at 16.degree. C. for 1 hour and at 22.degree. C. for 1 hour. The cDNA is then precipitated with two volumes of ethanol and 1/10 volume of sodium acetate at -70.degree. C. for 10 min, pelleted by centrifugation and dried. The pellet is resuspended in 100 .mu.l of T4 DNA polymerase buffer (20 mM (NH.sub.4).sub.2 SO.sub.4, 50 mM tris-HCl pH 8.8, 10 mM MgCl.sub.2, 50 .mu.m dNTP) and the reaction filling the cDNA ends is started by addition of 10 units of T4 DNA polymerase (Boehringer, Mannheim). The mixture is incubated at 37.degree. C. for 10 min and, after addition of 100 .mu.l of phenol/chloroform (1:1), phenolized. The cDNA solution is then centrifuged through a Sephacryl S 200 column (Pharmacia). The cDNA is precipitated from the eluate with two volumes of ethanol and 1/10 volume of sodium acetate, centrifuged and dried.

3) Ligation of the cDNA with EcoRI Adapter

The dried cDNA (1 .mu.g) was resuspended in 30 .mu.l of ligation buffer (30 mM tris-HCl pH 7.8, 10 mM MgCl.sub.2, 0.5 mM ATP, 10 mM DTT), 40 pmol of EcoRI adapter (Promega) and 7.5 units of T4 DNA ligase were added and the mixture was incubated at 14.degree. C. for 15 h. After inactivation of the ligase (10 min, 70.degree. C.) and, after addition of 4 .mu.l of kinase buffer (0.7 M tris-HCl pH 7.6, 0.1 M MgCl.sub.2, 50 mM DTT), 2 .mu.l of 0.1 mM ATP and 10 units of T4 polynucleotide kinase (Pharmacia), subsequent kinase treatment (30 min, 37.degree. C.), the cDNA is again centrifuged through a Sephacryl S 200 column and then precipitated with ethanol and sodium acetate as described above.

4) Ligation of the cDNA with lambda gt11 EcoRI Fragments, In Vitro Packaging and Transfection of lambda gt11

For the ligation reaction, about 50 ng of kinase-treated cDNA were added to 1 .mu.g of dephosphorylated lambda gt11 EcoRI fragments in 10 .mu.l of mixture (66 mM tris-HCl pH 7.6, 6.6 mM MgCl.sub.2, 1 mM ATP, 5 mM DTT) and, after addition of 3 Weiss units of T4 DNA ligase (Boehringer, Mannheim), the mixture was incubated at 14.degree. C. for 15 h. 5 .mu.l of this mixture are used in an in vitro packaging reaction which was carried out following the instructions of the packaging mix manufacturer (Giga Gold Mix, Stratagene).

After transfection of the E. coli strain Y1090, the titer of recombinant phages was determined. A total of about 10.sup.6 recombinant phages was obtained.

EXAMPLE 2

Screening of the lambda gt11 Expression Gene Bank Using a Hyperimmune Rabbit Anti-T. gondii Serum

Anti-E. coli antibodies were initially adsorbed out of the rabbit anti-T. gondii serum by known methods (L. S. Osaki (1986), J. Immun. Method. 89: 213-219; Promega Biotec (1986), ProtoBlot Immunoscreening System, Technical Manual) in order to reduce nonspecific reactions in the immunoblot. For this purpose, lambda gt11 wild type phages were distributed on a total of 30 LB-agar plates at a density of 5.times.10.sup.4 PFU in 9 ml of LB soft agar/0.4% maltose/10 mM MgSO.sub.4 per 90 mm agar plate. After incubation at 37.degree. C. for two hours, the plates were covered, in each case, with a dry round nitrocellulose filter equilibrated in 10 mM IPTG (isopropyl .beta.-D-thiogalactopyranoside) and incubated for a further two hours. The filters were then turned over and again incubated on the agar for two hours. The filters were then incubated in 5% skimmed milk power/TBS buffer (TBS: 150 mM NaCl, 50 mM tris-HCl pH 8.0) at room temperature for 10 min and, after the transfer into 100 ml of rabbit serum dilated 1/100 in 5% skimmed milk powder/TBS, incubated for four hours at room temperature. This pre-adsorbed, dilute serum was used both for the screening experiments and for Western blots. A total of 6.times.10.sup.5 recombinant phages of the lambda gt11 cDNA bank was subjected to screening with this serum by the method of R. Y. Young and R. W. Davis (Proc. Natl. Acad. Sci. 80: 1194 (1983)). For this purpose, cells of a culture of the E. coli K12 strain Y1090 were, as described above, transfected with recombinant lambda gt11 phages (3.times.10.sup.4 phages/100 .mu.l of Y1090 culture) and distributed on soft agar plates (20 plates total). After incubating for 2 h at 7.degree. C., the plates were, in each case, covered with a dry nitrocellulose filter soaked in 10 mM IPTG and incubated for a further 2 h. After the position of the filters on the agar plates had been marked, the filters were carefully lifted off and shaken in 250 ml of 5% skimmed milk powder/TBS buffer for 10 min at room temperature. The filters were then transferred into fresh skimmed milk powder/TBS buffer and stored at 4.degree. C. overnight.

After a further incubation of the filters in 250 ml of skimmed milk powder/TBS buffer, they were lightly shaken with 100 ml of the pre-adsorbed rabbit anti-T. gondii serum at room temperature for 1 h. Then the filters were washed three times with, in each case, 250 ml of TBS at room temperature for 10 min and shaken with 250 ml of anti-rabbit IgG/alkaline phosphatase IgG conjugate (Behringwerke, Marburg) diluted 1/300 in skimmed milk powder/TBS at room temperature for a further hour. After washing the filters (shaking three times with 250 ml of TBS at RT for 10 min each time), they were again incubated in 250 ml of a substrate solution for alkaline phosphatase (200 .mu.g/ml p-toluidine salt of 5-bromo-4-chloro-indoxy phosphate (XP), (from Bachem, order no.: M1205), 500 .mu.g/ml 4-nitrotetrazolium chloride blue (from Sigma, order no.: N6876)) for 15 min. Seropositive clones which can be recognized from the colored zone in the form of a ring around the phage plaque were matched up with the regions on the Petri dish, punched out using a Pasteur pipette and resuspended in 1 ml of SM buffer. Individual clones of the positive phage plaques were prepared in two further screening steps. A total of 83 seropositive clones was isolated. These clones were further characterized as follows.

1) Immunological characterization of the cDNA clones 2) Structural characterization of the cloned cDNA inserts a) DNA--DNA dot blot analyses b) Partial sequencing of the cDNA inserts in order to investigate the open reading frames c) Expression of the cloned cDNAs as a gene fusion with lacZ or lacZ' (partly deleted .beta.-galactosidase derivative) 3) Immunological Characterization of the Seropositive cDNA Clones

The seropositive clones of the gene bank were characterized immunologically by means of "clone-specific" sera (this refers to sera which have been obtained from the polyclonal rabbit serum by adsorption on the recombinant fusion protein of a cDNA clone). These sera were prepared in accordance with Ozaki et al. (J. Immun. Method. 89: 213-219 (1986)) as follows: 5.times.10.sup.4 PFU, in each case, of individual cDNA clones were, after adsorption to E. coli Y1090 cells, distributed on LB plates in soft agar and, after incubation for two hours, covered with, in each case, one nitrocellulose filter pretreated in 10 M IPTG, and the treatment was continued as described in Example 2. Three filters, pretreated in this way, per clone were, in each case, incubated in the pre-adsorbed rabbit serum for four hours and then washed in 50 ml of TBS for 10 min (3 changes of buffer). The antibodies bound on the filters were washed off using a total of 15 ml of a 0.1 M glycine/HCl buffer (pH 2.5) at room temperature for 5 min and were neutralized with 3 ml of 1 M tris. Skimmed milk powder was added to a final concentration of 5%.

Monospecific sera were generated from 20 independent clones. The immuno-reactivity of these sera to recombinant protein of all seropositive clones was tested in dotblod experiments. Clones whose recombinant proteins cross-reacted with a serum were grouped together in a clone group. In Southern dot blot analyses, .sup.32 P-labeled insert DNAs only showed a homology to the clone DNAs which were allocated to one group as a result of the above-described serological data. One clone was selected from each group and tested with human anti-T. gondii sera in a Western blot. For this purpose, the insert fragments of the clone DNAs were either subcloned into suitable expression vectors or the E. coli K12 strain Y1089 was lysogenized with the particular recombinant lambda gt11 derivatives.

EXAMPLE 4

Expression of the .beta.-Galactosidase Fusion Proteins

In order to investigate the immunoreactivity, the cDNA fragments of the lambda gt11 clones F2, F29, F28, F34, F61 and F76 were subcloned as gene fusions with a partly deleted lacZ derivative into vectors of the pSEM series (Knapp et al., Biotechniques (1990), 8:280) and the expression of the fusion proteins was induced in E. coli W3110 lacI.sup.q L8 (Brent and Ptashne (1981) Proc. Natl. Acad. Sci., 78: 4204-4208) by addition of IPTG. For the expression of the fusion proteins of clones F45 and F74, the E. coli strain Y1089 was lysogenized with both lambda gt11 derivatives and then the fusion proteins were induced by known methods (Huynh et al. in: Glover, DNA Cloning Volume I, p. 49-78, IRL Press, Oxford (1985)). The proteins from total cell extracts were, after IPTG induction, fractionated electrophoretically in SDS PAGE (10%) and transferred onto nitrocellulose. The reactivity of the recombinant proteins was verified in a Western blot using human IgG and IgM sera. Finally, the clones characterized in this way were sequenced.

EXAMPLE 5

Sequencing of the cDNA Fragments

The sequencing of the cDNA fragments was carried out by the dideoxy method of Sanger (Proc. Natl. Acad. Sci. (1977), 74: 5463) using the "KS primer" (Promega). The insert fragments of the clones F2, F29, F34, F28, F45, F61, F74 and F76 were cleaved out of recombinant lambda gt11 DNA using EcoRI and, after insertion into the EcoRI cleavage site of the vector Bluescript KS, transformed into the E. coli strain XL1-Blue (Stratagene, San Diego). Single-stranded DNA of these recombinant plasmids was, after infection of the clones with the helper phage VCS, isolated by known methods (Stratagene, San Diego). Depending on the orientation of the cloned fragments, the sequence of the 5' or the 3' end of the cDNA is obtained.

The Tables 1-8 (p. 5) show the translational reading frames (Tab. 1-6) and partial nucleotide sequences (Tab. 1-8) of the abovementioned clones.

EXAMPLE 6

Diagnostic Suitability of the Recombinant T. gondii Antigens rP35, rP66 and rP68

Partial sequences from the region of the structural genes of the antigens P35, P66 and P68 were expressed in E. coli W3110 using pSEM expression vectors (Knapp et al., Biotechniques (1990), 8:280). The expression products are composed of an N-terminal .beta.-galactosidase derivative of 375 aminoacids which contains an insert-specific fused portion at the C-terminus. The synthesis of the fusion proteins can be induced by IPTG as described in Knapp et al. (Biotechniques (1990), 8:280). For Western blot experiments, total cell extracts of recombinant E. coli W3110 derivatives were, after IPTG induction, fractionated in SDS PAGE. The proteins were transferred to Nitrocellulose paper, incubated with the specific serum sample and conjugate (antihuman IgG/alkaline phosphatase) and stained following a standard protocol (in: Sambrook et al.: Molecular Cloning, Cold Spring Harbor Laboratory Press (1989)). The following sections of the abovementioned T. gondii proteins were expressed:

rP35: base pairs 363-527*; contained in the hybrid plasmid pPS76 rP68: base pairs 176-1927*; contained in the hybrid plasmid pPS34 rP66: base pairs 1-2074*; contained in the hybrid plasmid pPS61 (* the coordinates of the nucleotide sequences refer to the data in the Tables 9-11).

The reactivity of specific IgG and IgM antibodies from human sera of patients having acute or chronic T. gondii infections was investigated in Western blot experiments. A summary of the results of these investigations is shown in Table 12. Thus all three hybrid proteins, rP35, rP66 and rP68, are suitable for the detection of specific IgG antibodies. Particular emphasis has to be laid on rP35:25/26 sera reacted with the hybrid protein in IgG Western blots; using rP68, specific IgG antibodies were recognized in 27/31 sera. Both fusion proteins, rP35 and rP68, without exception reacted with IgG anti-T. gondii anti-bodies from acute sera (n=21) which had a detectable specific IgM antibody titer. For this reason both rP35 and rP68 are particularly suitable as markers for the detection of IgG anti-T. gondii antibodies in the acute phase of toxoplasmosis.

rP66 reacted with most of the 21 sera tested in the IgM blot and is thus suitable as a marker for the detection of specific antibodies of this immunoglobulin class.

EXAMPLE 7

Suitability of the Recombinant T. gondii proteins rP35 and rP68 in ELISAs

The reactivity of the recombinant T. gondii proteins rP35 and rP68 with specific IgG antibodies was investigated in ELISAs. The two proteins were used as solid phase antigens either together or each by itself for coating ELISA plates. The two hybrid proteins were isolated from E. coli as follows:

An overnight culture of the recombinant E. coli strain W3110 containing the plasmids pPS76 or pPS34 was diluted 1/50 in 2 l of L-broth/100 mg/ml ampicillin and, with vigorous shaking, grown to a OD600=0.7 at 37.degree. C. After the addition of IPTG (final concentration 1 mM), the cultures were shaken vigorously at 37.degree. C. for a further 3 h, spun down and the cell pellet was taken up in 150 mM NaCl/50 mM tris-HCl pH 8.0/1 mg/ml lysozyme and incubated at 37.degree. C. for 10 min. For cell breakage, the cell suspension was treated 2.times. in a French press. The ruptured cells were centrifuged (10000 rpm, 10 min, 4.degree. C.) and the pellet containing the fusion protein present as sparingly soluble inclusion bodies was washed with a succession of urea solutions of varying concentrations (1 M-6 M urea). In this procedure, first the pellet was stirred in 30 ml of 1 M urea/10 mM tris/1 mM EDTA pH 8.0 (TE) at RT for 1 h. After centrifuging (10000 rpm, 10 min, 4.degree. C.), the pellet was taken up as described above in 2 M urea and incubated. These incubations were then continued with 3 M, 4 M, 5 M and 6 M urea. The supernatants after the centrifugation steps were stored and the proteins soluble therein analyzed in SDS PAGE. Those supernatants which, in addition to the fusion protein, only contained slight contaminations of E. coli protein (about 75% fusion protein) were used further for coating the ELISA plates. These supernatants were dialyzed against 1 M urea/0.1% SDS at 4.degree. C. for 72 h. For coating the ELISA plates, the protein concentration of the dialyzed samples was adjusted to 2 .mu.g/ml with PBS pH 7.0. The coating was carried out at 4.degree. C. overnight using 100 .mu.l/well. The plates were then washed 3.times. with AP washing buffer (Behring, order no.: 1353115) before the serum samples were applied to the plates.

Adsorption of anti-E. coli antibodies in serum samples: First, anti-E. coli antibodies were removed from the serum samples. For this purpose, the cells of an E. coli W3110 overnight culture were spun down and the pellet was resuspended in 5 ml of PBS pH 7.0. The cells were lyzed by ultrasound (sonication 3.times., Branson sonifier set to 7) and, after addition of DNAse I (final concentration 1 .mu.g/ml), incubated at 37.degree. C. for 10 min.

Human serum and lysate antigen were mixed in a ratio of 1:1, diluted 1/50 in PBS pH 7.0 and shaken at RT for 30 min. After the centrifugation, 5% skimmed milk/PBS pH 7.0 were added to the supernatant (final concentration 1%), 100 .mu.l/well thereof were incubated on ELISA plates at 37.degree. C. for 1 h and these were washed 3.times. with AP washing buffer.

Then 100 .mu.l/well of the anti-human IgG/AP conjugate (Behring order no.: OSDH 04/05) prediluted 1/70 in AP conjugate dilution buffer (Behring order no.: 1332115) were incubated at 37.degree. C. for 1 h. The plates were washed 3.times. with AP washing buffer and incubated with 100 .mu.l/well of AP substrate solution (Behring AP substrate tablets, order no.: OSCX 96; Behring 10% diethanolamine, order no.: 0243115; substrate solution: 2 tablets in 10 ml of 10% diethanolamine) at 37.degree. C. for 30 min and the optical density of the substrate solution was determined at 405 nm.

9 sera of a seroconverted patient (patient A1) were included in the investigations. The serum samples were taken from the donor on the following days: A, 9.8.1988; B, 18.8.1988; C, 29.8.1988; D, 12.10.1988; E, 2.12.1988; F, 13.1.1989; G, 28.2.1989; H, 12.5.1989; I, 17.7.1989. The infection took place on 31.7.1988, as can be proved. As can be seen from Tab. 13, human serum B, which was taken after day 17, shows specific IgG antibodies to rP35 and rP68 already. In contrast, this serum sample was negative in a classical, nonrecombinant ELISA system (IgG detection).

Moreover 30 human sera of donors with acute toxoplasmosis, which sera contained specific IgM antibodies, were analyzed for IgG antibodies to rP35 and rP68 in an ELISA. These human sera reacted without exception in the ELISA which contained both recombinant antigens rP35 and rP68 on the solid phase. Additionally 150 sera from blood donors were analyzed for specific IgG anti-rP35 and anti-rP68 antibodies. The same antisera were analyzed in the Enzygnost.RTM. toxoplasmosis (IgG; manufacturer: Behringwerke AG) for specific IgG antibodies and the results of the two tests were compared with each other. This showed that the sera which were positive in the Enzygnost.RTM. were also positive in the rP35/rP68 ELISA. For the anti-T. gondii-negative sera also, the data from the rP35/rP68 ELISA were consistent with those from the Enzygnost.RTM. ELISA.

TABLE 1a__________________________________________________________________________CATATACTGCACTGACTTCGACACCATGGAGCAAAGGCTGCCAATTATTCTACTTGTTCT+---------+---------+---------+---------+---------+ 50GTATATGACGTGACTGAAGCTGTGGTACCTCGTTTCCGACGGTTAATAAGATGAACAAGA I Y C T D F D T M E Q R L P I I L L V LCTCTGTGTTCTTCAGTTCAACCCCAAGCGCCGCCCTTTCGAGCCACAATGGAGTCCCCGC+---------+---------+---------+---------+---------+ 120GAGACACAAGAAGTCAAGTTGGGGTTCGCGGCGGGAAAGCTCGGTGTTACCTCAGGGGCG S V F F S S T F S A A L S S H N G V F ATTATCCATCGTATGCACAGGTATCGCTCTCTTCCAACGGCGAGCCACGGCACAGGGGCAT+---------+---------+---------+---------+---------+ 180AATAGGTAGCATACGTGTCCATAGCGAGAGAAGGTTGCCGCTCGGTGCCGTGTCCCCGTA Y P S Y A Q V S L S S N G E P R H R G IACGCGGCAGCTTCCTCATGTCCGTAAAGCCACACGCAAACGCTGATGACTTCGCCTCCGA+---------+---------+---------+---------+---------+ 240TGCGCCGTCGAAGGAGTACAGGCATTTCGGTGTGCGTTTGCGACTACTGAAGCGGAGGCT R G S F L M S V K F H A N A D D F A S DCGACAACTACGAACCGCTGCCGAGTTTCGTGGAAGCTCCTGTCAGAGGCCCGGACCAAGT+---------+---------+---------+---------+---------+ 300GCTGTTGATGCTTGGCGACGGCTCAAAGCACCTTCGAGGACAGTCTCCGGGCCTGGTTCA D N Y E F L P S F V E A P V R G P D Q VCCCTGCCAGAGGAGAAGCTGCTCTTGTCACAGAGGAGACTCCAGCGCAACAGCCGGCGGT+---------+---------+---------+---------+---------+ 360GGGACGGTCTCCTCTTCGACGAGAACAGTGTCTCCTCTGAGGTCGCGTTGTCGGCCGCCA P A R G E A A L V T E E T P A Q Q F A VGGCTCTAGGCAGTGCAGAAGGGGAGGGGACTCCACCTACTGAATCCGCCTCCGAAAATTC+---------+---------+---------+---------+---------+ 420CCGAGATCCGTCACGTCTTCCCCTCCCCTGAGGTGGATGACTTAGGCGGAGGCTTTTAAG A L G S A E G E G T F P T E S A S E N STGAAGATGATGACACGTTTCACGATGCCCTCCAAGAGCTTCCAGAGGATGGCCTCGAAGT+---------+---------+---------+---------+---------+ 480ACTTCTACTACTGTGCAAAGTGCTACGGGAGGTTCTCGAAGGTCTCCTACCGGAGCTTCA E D D D T F H D A L Q E L P E D G L E VGCGCCCACCAAATGCACAGGAGCTGCCCCCACCAAATGTACAGGAGCTGCCCCCACCAAA+---------+---------+---------+---------+---------+ 540CGCGGGTGGTTTACGTGTCCTCGACGGGGGTGGTTTACATGTCCTCGACGGGGGTGGTTT R F P N A Q E L P F F N V Q E L P P P NTGTACAGGAGCTGCCCCCACCAACTGAACAGGAGCTGCCCCCACCAACTGAACAGGAGCT+---------+---------+---------+---------+---------+ 600ACATGTCCTCGACGGGGGTGGTTGACTTGTCCTCGACGGGGGTGGTTGACTTGTCCTCGA V Q E L P P P T E Q E L F P F T E Q E L__________________________________________________________________________ TABLE 1b__________________________________________________________________________GCCCCCACCAACTGAACAGGAGCTGCCCCCACCAACTGAACAGGAGCTAGCCCCATCAAC+---------+---------+---------+---------+---------+ 660CGGGGGTGGTTGACTTGTCCTCGACGGGGGTGGTTGACTTGTCCTCGATCGGGGTAGTTGTGAACAGGAGCTGCCCCCACCAGTGGGCGAAGGTCAACGTCTGCAAGTCCCTGGGGAACA+---------+---------+---------+---------+---------+ 720ACTTGTCCTCGACGGGGGTGGTCACCCGCTTCCAGTTGCAGACGTTCAGGGACCCCTTGT E Q E L P P F V G E G Q R L Q V P G E HTGGGCCACAGGGGCCCCCATACGATGATCAGCAGCTGCTTTTAGAGCCTACGGAAGAGCA+---------+---------+---------+---------+---------+ 780ACCCGGTGTCCCCGGGGGTATGCTACTAGTCGTCGACGAAAATCTCGGATGCCTTCTCGT G P Q G P P Y D D Q Q L L L E F T E E QACAGGAGGGCCCTCAGGAGCCGCTGCCACCGCCGCCGCCCCCGACTCGGGGCGAACAACC+---------+---------+---------+---------+---------+ 840TGTCCTCCCGGGAGTCCTCGGCGACGGTGGCGGCGGCGGGGGCTGAGCCCCGCTTGTTGG Q E G F Q E P L P P P P P P T R G E Q PCGAAGGACAGCAGCCGCAGGGACCAGTTCGTCAAAATTTTTTTCGTCGGGCGTTGGGGGC+---------+---------+---------+---------+---------+ 900GCTTCCTGTCGTCGGCGTCCCTGGTCAAGCAGTTTTAAAAAAAGCAGCCCGCAACCCCCG E G Q Q P Q G F V R Q N F F R R A L G ACGCAAGAAGCCGATTCGGAGGTGCACGACGCCATGTCAGTGGGGTGTTCCGAAGAGTCAG+---------+---------+---------+---------+---------+ 960GCGTTCTTCGGCTAAGCCTCCACGTGCTGCGGTACAGTCACCCCACAAGGCTTCTCAGTC A R S R F G G A R R H V S G V F R R V RAGGTGGTTTGAACCGTATAGTAGGTGGAGTGAGGAGTGGTTTCAGGCGTGCAAGAGAAGG+---------+---------+---------+---------+---------+ 1020TCCACCAAACTTGGCATATCATCCACCTCACTCCTCACCAAAGTCCGCACGTTCTCTTCC G G L N R I V G G V R S G F R R A R E GTGTCGTTGGGGGAGTCCGTCGTTTAACAAGTGGTGCCAGTCTGGGTCTCGGTCGTGTAGG+---------+---------+---------+---------+---------+ 1080ACAGCAACCCCCTCAGGCAGCAAATTGTTCACCACGGTCAGACCCAGAGCCAGCACATCC V V G G V R R L T S G A S L G L G R V GAGAAGGTTTAGGTAGGAGTTTCTATCGTGTAAGAGGAGCTGTCAGTAGCGGTCGTAGGCG+---------+---------+---------+---------+---------+ 1140TCTTCCAAATCCATCCTCAAAGATAGCACATTCTCCTCGACAGTCATCGCCAGCATCCGC E G L G R S F Y R V R G A V S S G R R RTGCAGCAGATGGTGCCAGCAATGTAAGAGAAAGATTCGT+---------+---------+--------- 1179ACGTCGTCTACCACGGTCGTTACATTCTCTTTCTAAGCA A A D G A S N V R E R F__________________________________________________________________________ TABLE 2a__________________________________________________________________________CTGAACAGGAGGGTTTGCCGGAAACAGAGGTGGCGCATCAGCATGAGACAGAAGAACAGT+---------+---------+---------+---------+---------+ 60GACTTGTCCTCCCAAACGGCCTTTGTCTCCACCGCGTAGTCGTACTCTGTCTTCTTGTCA E Q E G L P E T E V A H Q H E T E E Q Y ACGGGACTGAAGGGATGCCCCCCCCTGTTCTGCCACCTGCACCGGTAGTCCATCCGCGTT+---------+---------+---------+---------+---------+ 120TGCCCTGACTTCCCTACGGGGGGGGACAAGACGGTGGACGTGGCCATCAGGTAGGCGCAA G T E G M P F P V L P P A P V V H P R F TTATTGCAGTACCAGGGCCGTCGGTGCCTGTTCCATTTTTCAGTTTGCCAGACATCCACC+---------+---------+---------+---------+---------+ 180AATAACGTCATGGTCCCGGCAGCCACGGACAAGGTAAAAAGTCAAACGGTCTGTAGGTGG I A V P G P S V P V P F F S L P D I H P CGGATCAGGTTGTGTATATTCTAAGGGTTCAGGGATCTGGGGACTTCGACATCAGTTTCG+---------+---------+---------+---------+---------+ 240GCCTAGTCCAACACATATAAGATTCCGAAGTCCCTAGACCCCTGAAGCTGTAGTCAAAGC D Q V V Y I L R V Q G S G D F D I S F E AAGTTGGCCGAGCTGTGAAGCAGTTGGAAGCCATCAAGAAAGCATACAGAGAAGCCACCG+---------+---------+---------+---------+---------+ 300TTCAACCGGCTCGACACTTCGTCAACCTTCGGTAGTTCTTTCGTATGTCTCTTCGGTGGC V G R A V K Q L E A I K K A Y R E A T G GGAAGCTAGAAGCAGACGAGCTTGAGTCAGAAAGGGGACCTGCTGTTTCACCTCGACGAA+---------+---------+---------+---------+---------+ 360CCTTCGATCTTCGTCTGCTCGAACTCAGTCTTTCCCCTGGACGACAAAGTGGAGCTGCTT K L E A D E L E S E R G P A V S P R R R GGCTGGTTGACCTGATCAAAGATAACCAGCGACGACTCAGGGCGGCGCTTCAGAAGATAA+---------+---------+---------+---------+---------+ 420CCGACCAACTGGACTAGTTTCTATTGGTCGCTGCTGAGTCCCGCCGCGAAGTCTTCTATT L V D L I K D N Q R R L R A A L Q K I K AGATACAGAAAAAGTTGGAGGAGATTGATGACTTACTTCAGCTGACACGCGCACTGAAGG+---------+---------+---------+---------+---------+ 480TCTATGTCTTTTTCAACCTCCTCTAACTACTGAATGAAGTCGACTGTGCGCGTGACTTCC I Q K K L E E I D D L L Q L T R A L K A CCATGGATGCCCGTCTGAGAGCCTGCCAGGATATGGCACCGATTGAGGAGGCGCTGTGTC+---------+---------+---------+---------+---------+ 540GGTACCTACGGGCAGACTCTCGGACGGTCCTATACCGTGGCTAACTCCTCCGCGACACAG M D A R L R A C Q D M A P I E E A L C H ACAAGACGAAGGCGTTTGGAGAAATGGTGTCCCAGAAAGCCAAGGAAATTCGGGAGAAAG+---------+---------+---------+---------+---------+ 600TGTTCTGCTTCCGCAAACCTCTTTACCACAGGGTCTTTCGGTTCCTTTAAGCCCTCTTTC K T K A F G E M V S Q K A K E I R E K A__________________________________________________________________________ TABLE 2b__________________________________________________________________________CGGCGTCCTTGTCTTCATTGTTAGGTGTCGATGCTGTCGAAAAAGAATTGCGGCGTGTCG+---------+---------+---------+---------+---------+ 660GCCGCAGGAACAGAAGTAACAATCCACAGCTACGACAGCTTTTTCTTAACGCCGCACAGC A S L S S L L G V D A V E K E L R R V EAACCGGAACATGAAGATAACACCAGAGTTGAAGCCAGGGTAGAGGAATTGCAGAAGGCGC+---------+---------+---------+---------+---------+ 720TTGGCCTTGTACTTCTATTGTGGTCTCAACTTCGGTCCCATCTCCTTAACGTCTTCCGCG P E H E D N T R V E A R V E E L Q K A LTGGAGAAGGCCGCGTCTGAGGCAAAGCAGCTCGTGGGGACCGCAGCAGGCGAAATAGAGG+---------+---------+---------+---------+---------+ 780ACCTCTTCCGGCGCAGACTCCGTTTCGTCGAGCACCCCTGGCGTCGTCCGCTTTATCTCC E K A A S E A K Q L V G T A A G E I E EAAGGAGTAAAAGCGGATACTCAGGCTGTGCAAGATAGCTCGAAAGACGTGTTGACGAAGA+---------+---------+---------+---------+---------+ 840TTCCTCATTTTCGCCTATGAGTCCGACACGTTCTATCGAGCTTTCTGCACAACTGCTTCT G V K A D T Q A V Q D S S K D V L T K SGTCCAGTTGCGCTCGTGGAAGCCTTTAAAGCGATCCAGAGGGCTCTTCTTGAGGCGAAGA+---------+---------+---------+---------+---------+ 900CAGGTCAACGCGAGCACCTTCGGAAATTTCGCTAGGTCTCCCGAGAAGAACTCCGCTTCT F V A L V E A F K A I Q R A L L E A K TCAAAGGAACTAGTAGAGCCTA+---------+- 921GTTTCCTTGATCATCTCGGAT K E L V E P__________________________________________________________________________ TABLE 3__________________________________________________________________________GCCGGAACTAACAGAGGAGCAACAGAGAGGCGACGAACCCCTAACCACCGGCCAGAATGT+---------+---------+---------+---------+---------+ 60CGGCCTTGATTGTCTCCTCGTTGTCTCTCCGCTGCTTGGGGATTGGTGGCCGGTCTTACA P E L T E E Q Q R G D E P L T T G Q N VGGGCACTGTGTTAGGCTTCGCAGCGCTTGCTGCTGCCGCAGCGTTCCTTGGCATGGGTCT+---------+---------+---------+---------+---------+ 120CCCGTGACACAATCCGAAGCGTCGCGAACGACGACGGCGTCGCAAGGAACCGTACCCAGA G T V L G F A A L A A A A A F L G M G LCACGAGGACGTACCGACATTTTTCCCCACGCAAAAACAGATCACGGCAGCCTGCACTCGA+---------+---------+---------+---------+---------+ 180GTGCTCCTGCATGGCTGTAAAAAGGGGTGCGTTTTTGTCTAGTGCCGTCGGACGTGAGCT T R T Y R H F S P R K N R S R Q P A L EGCAAGAGGTGCCTGAATCAGGCGAAGATGGGGAGGATGCCCGCCAG+---------+---------+---------+------ 226CGTTCTCCACGGACTTAGTCCGCTTCTACCCCTCCTACGGGCGGTC Q E V F E S G E D G E D A R Q__________________________________________________________________________ TABLE 4__________________________________________________________________________CCGTTGCTGTCGGGGTGCTATCTTCTCCCACCTTTTATCAGTTAAGTTGTACAGTGAGTG+---------+---------+---------+---------+---------+ 60GGCAACGACAGCCCCACGATAGAAGAGGGTGGAAAATAGTCAATTCAACATGTCACTCAC R C C R G A I F S H L L S V K L Y S E CTCAGCTTGTTTCGACACGTCTGTATAGACGCAACTCGGTTTGCTTGTGTTGTTTGGTGGC+---------+---------+---------+---------+---------+ 120AGTCGAACAAAGCTGTGCAGACATATCTGCGTTGAGCCAAACGAACACAACAAACCACCG Q L V S T R L Y R R N S V C L C C L V ATGGCCAAATCAAAGGCTATTCATTTTTCACTTGCTGTTGTTCTTTGAAGAAATCAAGCAA+---------+---------+---------+---------+---------+ 180ACCGGTTTAGTTTCCGATAAGTAAAAAGTGAACGACAACAAGAAACTTCTTTAGTTCGTT G Q I K G Y S F F T C C C S L K K S S KGATGGTGCGTGTGAGCGCTATTGTCGGAGCTGCTGCATCGGTGTTCGTGTGCCTGTCTGC+---------+---------+---------+---------+---------+ 240CTACCACGCACACTCGCGATAACAGCCTCGACGACGTAGCCACAAGCACACGGACAGACG M V R V S A I V G A A A S V F V C L S ACGGCGCTTACGCTGCCGAAGGCGGCGACAACCAGTCGAGCGCCGTCTCAGATCGGGCGTC+---------+---------+---------+---------+---------+ 300 -GCCGCGAATGCGACGGCTTCCGCCGCTGTTGGTCAGCTCGCGGCAGAGTCTAGCCCGCAG G A Y A A E G G D N Q S S A V S D R A STCTCTTTGGTTTGCTGAGTGGAGGGACAGGGCA+---------+---------+--- 333AGAGAAACCAAACGACTCACCTCCCTGTCCCGT L F G L L S G G T G__________________________________________________________________________ TABLE 5__________________________________________________________________________CAGTTTCGCGCGTCCCGTTTCCACGGACAAAATGGCAATGAAATACGTCGCTGCTTACCT+---------+---------+---------+---------+---------+ 60GTCAAAGCGCGCAGGGCAAAGGTGCCTGTTTTACCGTTACTTTATGCAGCGACGAATGGA S E A R F V S T D K M A M K Y V A A Y LGATGGTGGTGCTGTCGGGAACCGACACTCCGACCAAGAAGCAGGTTGAGAAAACCCTCTC+---------+---------+---------+---------+---------+ 120CTACCACCACGACAGCCCTTGGCTGTGAGGCTGGTTCTTCGTCCAACTCTTTTGGGAGAG M V V L S G T D T P T K K Q V E K T L SCTCTGTGGGTATTGATGTTGAAGACGACATCATGGACACCTTCTTCAAAGCTGTCGAAGG+---------+---------+---------+---------+---------+ 180GAGACACCCATAACTACAACTTCTGCTGTAGTACCTGTGGAAGAAGTTTCGACAGCTTCC S V G I D V E D D I M D T F F K A V E GAAAGACCCCCCACGAGCTGATTGCCGCGGGTATGGAGAAGCTCCAGAAGGTACCTTCTGG+---------+---------+---------+---------+---------+ 240TTTCTGGGGGGTGCTCGACTAACGGCGCCCATACCTCTTCGAGGTCTTCCATGGAAGACC K T P H E L I A A G M E K L Q K V P S GTGGTGTCGCTGCTGCTGCTGCTCCTGCTGCTGGCGCTGCCGATGCTGGTGCGGGTGCTGC+---------+---------+---------+---------+---------+ 300ACCACAGCGACGACGACGACGAGGACGACGACCGCGACGGCTACGACCACGCCCACGACG G V A A A A A P A A G A A D A G A G A ATGCTGCGAAGAAGGAGGAGGAAAAGAAGGAGGAAGAGGAGGAGGAAGACGACATG+---------+---------+---------+---------+----- 355ACGACGCTTCTTCCTCCTCCTTTTCTTCCTCCTTCTCCTCCTCCTTCTGCTGTAC A A K K E E E K K E E E E E E D D M__________________________________________________________________________ TABLE 6__________________________________________________________________________GCCACAGCCAGAGATACCGCCTGTTCATCGGCCGCCGCCTCCGGGTTTCCGTCCCGAAGT+---------+---------+---------+---------+---------+ 60CGGTGTCGGTCTCTATGGCGGACAAGTAGCCGGCGGCGGAGGCCCAAAGGCAGGGCTTCA P Q P E I P P V H R P P P P G F R P E VGGCTCCCGTGCCCCCGTATCCAGTGGGCACTCCAACGGGCATGCCCCAGCCGGAGATACC+---------+---------+---------+---------+---------+ 120CCGAGGGCACGGGGGCATAGGTCACCCGTGAGGTTGCCCGTACGGGGTCGGCCTCTATGG A P V P P Y P V G T P T G M P Q P E I PGGCAGTTCACCATCCGTTCCCCTACGTTACGACAACCACGACAG+---------+---------+---------+---- 164CCGTCAAGTGGTAGGCAAGGGGATGCAATGCTGTTGGTGCTGTC A V H H P F P Y V T T T T T__________________________________________________________________________ TABLE 7__________________________________________________________________________ATATATGTGTCTCGTGCTTGAGTGTGTTCTTTGTATGATCAAAACTCGTTAAAATGCGCA+---------+---------+---------+---------+---------+ 60TATATACACAGAGCACGAACTCACACAAGAAACATACTAGTTTTGAGCAATTTTACGCGTCGTTACCGCATGGGTAGTAGTTCGAGACAGCTTGTGTGTACCTGAGGGGCCGCGTGTTGC+---------+---------+---------+---------+---------+ 120GCAATGGCGTACCCATCATCAAGCTCTGTCGAACACACATGGACTCCCCGGCGCACAACGCAAAAGTGCCTAGTCTTACACGGCCGACAAGAGGGTTCCTCGGTTCTTCTCTGCGTTCTT+---------+---------+---------+---------+---------+ 180GTTTTCACGGATCAGAATGTGCCGGCTGTTCTCCCAAGGAGCCAAGAAGAGACGCAAGAACCTTCTCCCATCCGATTCTTCAAGTTCTGAACAAATCTGTCGTGTCTCGACTGATGTGCG+---------+---------+---------+---------+---------+ 240GGAAGAGGGTAGGCTAAGAAGTTCAAGACTTGTTTAGACAGCACAGAGCTGACTACACGCTGCGTTTTGA+ 250ACGCAAAACT__________________________________________________________________________ TABLE 8__________________________________________________________________________GGAATTCTTGTTACGCGGTCAGATGTTTCTTGAGTAGTGAATCAAAATGTATTATGGTGT+---------+---------+---------+---------+---------+ 60CCTTAAGAACAATGCGCCAGTCTACAAAGAACTCATCACTTAGTTTTACATAATACCACAAATCCTGTCAGTTTTATACGTATTGTCATACGTCCACGCATCTCACGTACGGGCGCGAAC+---------+---------+---------+---------+---------+ 120TTAGGACAGTCAAAATATGCATAACAGTATGCAGGTGCGTAGAGTGCATGCCCGCGCTTGGCAGCAAGTGACGAGAGATCATCCCACTCGTTTGGTGACGCTGCAAAATACAAGTGTATT+---------+---------+---------+---------+---------+ 180CGTCGTTCACTGCTCTCTAGTAGGGTGAGCAAACCACTGCGACGTTTTATGTTCACATAAATACGGTCAGTCGGCTCTACAACATTCAAAACGAGTTGTCTCGCTTCAACCACAAAGCGC+---------+---------+---------+---------+---------+ 240TATGCCAGTCAGCCGAGATGTTGTAAGTTTTGCTCAACAGAGCGAAGTTGGTGTTTCGCGCACACT 246__________________________________________________________________________GTGTGA TABLE 9__________________________________________________________________________Nucleotide sequence of the cDNA and amino-acid sequencederived therefrom of the T.gondii antigen P35__________________________________________________________________________ CAGTTTCCGCGCTGTAGTAAGATGGCTTTACCATTGCGTGTTTCGGCCACGGTGTTCGTG 1+---------+---------+---------+---------+---------+ 60 GTCAAAGGCGCGACATCATTCTACCGAAATGGTAACGCACAAAGCCGGTGCCACAAGCAC MetAiaLeuProLeuArgVaiSerAiaThrVaiPheVal GTCTTCGCTGTCTTTGGTGTAGCTCGCGCCATGAACGGTCCTTTGAGTTATCATCCAAGC 61+---------+---------+---------+---------+---------+ 120 CAGAAGCGACAGAAACCACATCGAGCGCGGTACTTGCCAGGAAACTCAATAGTAGGTTCG ValPheAlaValPheGlyValAlaArgAlaMetAsnGlyProLeuSerTyrHisProSer AGTTACGGAGCGTCGTATCCGAATCCGAGTAATCCTCTGCATGGAATGCCCAAGCCAGAG 121+---------+---------+---------+---------+---------+ 180 TCAATGCCTCGCAGCATAGGCTTAGGCTCATTAGGAGACGTACCTTACGGGTTCGGTCTC SerTyrGlyAlaSerTyrProAsnProSerAsnProLeuHisGlyMetProLysProGlu AACCCGGTGAGACCGCCTCCTCCCGGTTTCCATCCAAGCGTTATTCCCAATCCCCCGTAC 181+---------+---------+---------+---------+---------+ 240 TTGGGCCACTCTGGCGGAGGAGGGCCAAAGGTAGGTTCGCAATAAGGGTTAGGGGGCATG AsnProValArgProProProProGlyPheHisProSerValIleProAsnProProTyr CCGCTGGGCACTCCAGCGAGCATGCCACAGCCAGAGGTTCCGCCACTTCAGCATCCCCCG 241+---------+---------+---------+---------+---------+ 300 GGCGACCCGTGAGGTCGCTCGTACGGTGTCGGTCTCCAAGGCGGTGAAGTCGTAGGGGGC ProLeuGlyThrProAlaSerMetProGlnProGluValProProLeuGlnHisProPro CCAACGGGTTCCCCTCCCGCGGCCGCTCCCCAGCCTCCATATCCAGTGGGTACTCCAGTA 301+---------+---------+---------+---------+---------+ 360 GGTTGCCCAAGGGGAGGGCGCCGGCGAGGGGTCGGAGGTATAGGTCACCCATGAGGTCAT ProThrGlySerProProAlaAlaAlaProGlnProProTyrProValGlyThrProVal ATGCCACAGCCAGAGATACCGCCTGTTCATCGGCCGCCGCCTCCGGGTTTCCGTCCCGAA 361+---------+---------+---------+---------+---------+ 420 TACGGTGTCGGTCTCTATGGCGGACAAGTAGCCGGCGGCGGAGGCCCAAAGGCAGGGCTT MetProGlnProGluIleProProValHisArgProProProProGlyPheArgProGlu GTGGCTCCCGTGCCCCCGTATCCAGTGGGCACTCCAACGGGCATGCCCCAGCCGGAGATA 421+---------+---------+---------+---------+---------+ 480 CACCGAGGGCACGGGGGCATAGGTCACCCGTGAGGTTGCCCGTACGGGGTCGGCCTCTAT ValAlaProValProProTyrProValGlyThrProThrGlyMetProGlnProGluIle CCGGCAGTTCACCATCCGTTCCCCTACGTTACGACAACCACGACAGCTGCTCCTCGTGTG 481+---------+---------+---------+---------+---------+ 540 GGCCGTCAAGTGGTAGGCAAGGGGATGCAATGCTGTTGGTGCTGTCGACGAGGAGCACAC ProAlaValHisHisProPheProTyrValThrThrThrThrThrAlaAlaProArgVal CTGGTTTATAAGATTCCCTATGGAGGCGCTGCACCCCCCCGTGCTCCTCCAGTGCCACCC 541+---------+---------+---------+---------+---------+ 600 GACCAAATATTCTAAGGGATACCTCCGCGACGTGGGGGGGCACGAGGAGGTCACGGTGGG LeuValTyrLysIleProTyrGlyG1yAlaAlaProProArgAlaProProValProPro CGTATGGGCCCGAGTGATATCAGCACTCACGTGCGGGGTGCAATCCGGCGTCAACCCGGT 601+---------+---------+---------+---------+---------+ 660 GCATACCCGGGCTCACTATAGTCGTGAGTGCACGCCCCACGTTAGGCCGCAGTTGGGCCA ArgMetGlyProSerAspIleSerThrHisValArgGlyAlaIleArgArgGlnProGly ACCACCACCACCACTACTTCCCGCAAACTACTATTCAGGACAGCGGTAGTGGCTGCAATG 661+---------+---------+---------+---------+---------+ 720 TGGTGGTGGTGGTGATGAAGGGCGTTTGATGATAAGTCCTGTCGCCATCACCGACGTTAC ThrThrThrThrThrThrSerArgLysLeuLeuPheArgThrAlaValValAlaAlaMet GCAGCAGCCTTGATAACCCTGTTCAGACAAAGACCTGTGTTCATGGAGGGGGTACGGATG 721+---------+---------+---------+---------+---------+ 780 CGTCGTCGGAACTATTGGGACAAGTCTGTTTCTGGACACAAGTACCTCCCCCATGCCTAC AlaAlaAlaLeuIleThrLeupheArgGlnArgProValPheMetGluGlyValArgMet TTTCCAAATCTCCACTACAGATTCACCGTAACGACGCAGAATTAAATTTCCGGTTGACGA 781+---------+---------+---------+---------+---------+ 840 AAAGGTTTAGAGGTGATGTCTAAGTGGCATTGCTGCGTCTTAATTTAAAGGCCAACTGCT PheProAsnLeuHisTyrArgPheThrValThrThrGlnAsn ATATAGAAGTCACTTATACAGTGGGTACACGACCTTCGTGGCGTCCACACCTTGTTTCCG 841+---------+---------+---------+---------+---------+ 900 TATATCTTCAGTGAATATGTCACCCATGTGCTGGAAGCACCGCAGGTGTGGAACAAAGGC TTCCGGTCACAGGTTGTGTCTACAAACGAACACGGTGGTATGTGCTGTAGACTCAGGGGT 901+---------+---------+---------+---------+---------+ 960 AAGGCCAGTGTCCAACACAGATGTTTGCTTGTGCCACCATACACGACATCTGAGTCCCCA GGGAGGAGCGCTGTAGGGCCTTCTGGAGAGCTCTCAATGTGCGCTATCCGCTTATATTCG 961+---------+---------+---------+---------+---------+ 1020 CCCTCCTCGCGACATCCCGGAAGACCTCTCGAGAGTTACACGCGATAGGCGAATATAAGC TGCAGCGTTATCCTCGTGAGGAGCGTCGATTGTGTCGTGCCCAGTGTCGCCGGACTCGAA1021+---------+---------+---------+---------+---------+ 1080 ACGTCGCAATAGGAGCACTCCTCGCAGCTAACACAGCACGGGTCACAGCGGCCTGAGCTT TCAGAAACCTGC1081+-- 1092 AGTCTTTGGACG__________________________________________________________________________ Table 10__________________________________________________________________________Nucleotide sequence of the CDNA and amino-acid sequencederived therefrom of the T.gondii antigen P.66__________________________________________________________________________ TTGCTGTCGCCGTTGCTGTCGCATATACTGCACTGACTTCGACACCATGGAGCAAAGGCT--------+---------+---------+---------+---------+---------+ 60 AACGACAGCGGCAACGACAGCGTATATGACGTGACTGAAGCTGTGGTACCTCGTTTCCGA MetGluGlnArgLe GCCAATTATTCTACTTGTTCTCTCTGTGTTCTTCAGTTCAACCCCAAGCGCCGCCCTTTC--------+---------+---------+---------+---------+---------+ 120 CGGTTAATAAGATGAACAAGAGAGACACAAGAAGTCAAGTTGGGGTTCGCGGCGGGAAAG uProIleIleLeuLeuValLeuSerValPhePheSerSerThrProSerAlaAlaLeuSe GAGCCACAATGGAGTCCCCGCTTATCCATCGTATGCACAGGTATCGCTCTCTTCCAACGG--------+---------+---------+---------+---------+---------+ 180 CTCGGTGTTACCTCAGGGGCGAATAGGTAGCATACGTGTCCATAGCGAGAGAAGGTTGCC rSerHisAsnGlyValProAlaTyrProSerTyrAlaGlnValSerLeuSerSerAsnGl CGAGCCACGGCACAGGGGCATACGCGGCAGCTTCCTCATGTCCGTAAAGCCACACGCAAA--------+---------+---------+---------+---------+---------+ 240 GCTCGGTGCCGTGTCCCCGTATGCGCCGTCGAAGGAGTACAGGCATTTCGGTGTGCGTTT yGluProArgHisArgGlyIleArgGlySerPheLeuMetSerValLysProHisAlaAs CGCTGATGACTTCGCCTCCGACGACAACTACGAACCGCTGCCGAGTTTCGTGGAAGCTCC--------+---------+---------+---------+---------+---------+ 300 GCGACTACTGAAGCGGAGGCTGCTGTTGATGCTTGGCGACGGCTCAAAGCACCTTCGAGG nAlaAspAspPheAlaSerAspAspAsnTyrGluProLeuProSerPheValGluAlaPr TGTCAGAGGCCCGGACCAAGTCCCTGCCAGAGGAGAAGCTGCTCTTGTCACAGAGGAGAC--------+---------+---------+---------+---------+---------+ 360 ACAGTCTCCGGGCCTGGTTCAGGGACGGTCTCCTCTTCGACGAGAACAGTGTCTCCTCTG oValArgGlyProAspGlnValProAlaArgGlyGluAlaAlaLeuValThrGluGluTh TCCAGCGCAACAGCCGGCGGTGGCTCTAGGCAGTGCAGAAGGGGAGGGGACTCCACCTAC--------+---------+---------+---------+---------+---------+ 420 AGGTCGCGTTGTCGGCCGCCACCGAGATCCGTCACGTCTTCCCCTCCCCTGAGGTGGATG rProAlaGlnGlnProAlaValAlaLeuGlySerAlaGluGlyGluGlyThrProProTh TGAATCCGCCTCCGAAAATTCTGAAGATGATGACACGTTTCACGATGCCCTCCAAGAGCT--------+---------+---------+---------+---------+---------+ 480 ACTTAGGCGGAGGCTTTTAAGACTTCTACTACTGTGCAAAGTGCTACGGGAGGTTCTCGA rGluSerAlaSerGluAsnSerGluAspAspAspThrPheHisAspAlaLeuGlnGluLe TCCAGAGGATGGCCTCGAAGTGCGCCCACCAAATGCACAGGAGCTGCCCCCACCAAATGT--------+---------+---------+---------+---------+---------+ 540 AGGTCTCCTACCGGAGCTTCACGCGGGTGGTTTACGTGTCCTCGACGGGGGTGGTTTACA uProGluAspGlyLeuGluValArgProProAsnAlaGlnGluLeuProProProAsnVa ACAGGAGCTGCCCCCACCAAATGTACAGGAGCTGCCCCCACCAACTGAACAGGAGCTGCC--------+---------+---------+---------+---------+---------+ 600 CCCACCAACTGAACAGGAGCTGCCCCCACCAACTGAACAGGAGCTGCCCCCACCAACTGA lGlnGluLeuProProProAsnValGlnGluLeuProProProThrGluGlnGluLeuPr CCCACCAACTGAACAGGAGCTGCCCCCACCAACTGAACAGGAGCTGCCCCCACCAACTGA--------+---------+---------+---------+---------+---------+ 660 GGGTGGTTGACTTGTCCTCGACGGGGGTGGTTGACTTGTCCTCGACGGGGGTGGTTGACT oProProThrGluGlnGluLeuproproproThrGluGlnGluLeuProProProThrGl ACAGGAGCTAGCCCCATCAACTGAACAGGAGCTGCCCCCACCAGTGGGCGAAGGTCAACG--------+---------+---------+---------+---------+---------+ 720 TGTCCTCGATCGGGGTAGTTGACTTGTCCTCGACGGGGGTGGTCACCCGCTTCCAGTTGC uGlnGluLeuAlaProSerThrGluGlnGluLeuProProProValGlyGluGlyGlrAr TCTGCAAGTCCCTGGGGAACATGGGCCACAGGGGCCCCCATACGATGATCAGCAGCTGCT--------+---------+---------+---------+---------+---------+ 780 AGACGTTCAGGGACCCCTTGTACCCGGTGTCCCCGGGGGTATGCTACTAGTCGTCGACGA gLeuGlnValproGlyGluHisGlyproGlnGlyproProTyrAspAspGlnGlnLeuLe TTTAGAGCCTACGGAAGAGCAACAGGAGGGCCCTCAGGAGCCGCTGCCACCGCCGCCGCC--------+---------+---------+---------+---------+---------+ 840 AAATCTCGGATGCCTTCTCGTTGTCCTCCCGGGAGTCCTCGGCGACGGTGGCGGCGGCGG uLeuGluProThrGluGluGlnGlnGluGlyProGlnGluProLeuProProProProPr CCCGACTCGGGGCGAACAACCCGAAGGACAGCAGCCGCAGGGACCAGTTCGTCAAAATTT--------+---------+---------+---------+---------+---------+ 900 GGGCTGAGCCCCGCTTGTTGGGCTTCCTGTCGTCGGCGTCCCTGGTCAAGCAGTTTTAAA oProThrArgGlyGluGlnProGluGlyGlnGlnProGlnGlyProValArgGlnAsnPh TTTTCGTCGGGCGTTGGGGGCCGCAAGAAGCCGATTCGGAGGTGCACGACGCCATGTCAG--------+---------+---------+---------+---------+---------+ 960 AAAAGCAGCCCGCAACCCCCGGCGTTCTTCGGCTAAGCCTCCACGTGCTGCGGTACAGTC ePheArgArgAlaLeuGlyAlaAlaArgSerArgPheGlyGlyAlaArgArgHisValSe TGGGGTGTTCCGAAGAGTCAGAGGTGGTTTGAACCGTATAGTAGGTGGAGTGAGGAGTGG--------+---------+---------+---------+---------+---------+ 1020 ACCCCACAAGGCTTCTCAGTCTCCACCAAACTTGGCATATCATCCACCTCACTCCTCACC rGlyValPheArgArgValArgGlyGlyLeuAsnArgIleValGlyGlyValArgSerGl TTTCAGGCGTGCAAGAGAAGGTGTCGTTGGGGGAGTCCGTCGTTTAACAAGTGGTGCCAG--------+---------+---------+---------+---------+---------+ 1080 AAAGTCCGCACGTTCTCTTCCACAGCAACCCCCTCAGGCAGCAAATTGTTCACCACGGTC yPheArgArgAlaArgGluGlyVa1Va1GlyGlyValArgArgLeuThrSerGlyAlaSe TCTGGGTCTCGGTCGTGTAGGAGAAGGTTTAGGTAGGAGTTTCTATCGTGTAAGAGGAGC--------+---------+---------+---------+---------+---------+ 1140 AGACCCAGAGCCAGCACATCCTCTTCCAAATCCATCCTCAAAGATAGCACATTCTCCTCG rLeuGlyLeuGlyArgValGlyGluGlyLeuGlyArgSerPheTyrArgValArgGlyAl TGTCAGTAGCGGTCGTAGGCGTGCAGCAGATGGTGCCAGCAATGTAAGAGAAAGATTCGT--------+---------+---------+---------+---------+---------+ 1200 ACAGTCATCGCCAGCATCCGCACGTCGTCTACCACGGTCGTTACATTCTCTTTCTAAGCA aValSerSerGlyArgArgArgAlaAlaAspGlyAlaSerAsnValArgGluArgPheVa TGCCGCAGGCGGGAGAGTCAGAGACGCTTTCGGCGCGGGATTGACGCGCCTCCGCAGGCG--------+---------+---------+---------+---------+---------+ 1260 ACGGCGTCCGCCCTCTCAGTCTCTGCGAAAGCCGCGCCCTAACTGCGCGGAGGCGTCCGC lAlaAlaGlyGlyArgVa1ArgAspAlaPheGlyAlaGlyLeuThrArgLeuArgArgAr CGGCAGAACTAATGGCGAGGAGGGCAGGCCCCTACTGGGCGAAGGAAGAGAGCAGGATGA--------+---------+---------+---------+---------+---------+ 1320 GCCGTCTTGATTACCGCTCCTCCCGTCCGGGGATGACCCGCTTCCTTCTCTCGTCCTACT gGlyArgThrAsnGlyGluGluGlyArgProLeuLeuGlyGluGlyArgGluGlnAspAs TGGATCGCAATAATACGGGCAGCATGCTGCTGGATTCGGCGAAGACGACCGTTTCTCGTA--------+---------+---------+---------+---------+---------+ 1380 ACCTAGCGTTATTATGCCCGTCGTACGACGACCTAAGCCGCTTCTGCTGGCAAAGAGCAT pGlySerGln AACGACAGCGGGTCCTCCGAAGTTAAGAAACCCGGTAAACGTGTGTGCCGTAACGGTGAT--------+---------+---------+---------+---------+---------+ 1440 TTGCTGTCGCCCAGGAGGCTTCAATTCTTTGGGCCATTTGCACACACGGCATTGCCACTA CGAGTTTGCAGATGGTTCCTTGTGTACCACGTGGCTTCTCGAGACCAATCGTGCTTTGTT--------+---------+---------+---------+---------+---------+ 1500 GCTCAAACGTCTACCAAGGAACACATGGTGCACCGAAGAGCTCTGGTTAGCACGAAACAA AGGGTCTAGTAGTTCGGACAGGATTTTATTGAACTGCAGGAATGCTTGCAGAAGAGAAGC--------+---------+---------+---------+---------+---------+ 1560 TCCCAGATCATCAAGCCTGTCCTAAAATAACTTGACGTCCTTACGAACGTCTTCTCTTCG CGTGAGGCAATGCAGGTTCTTGCGTCTGTGCGAGCAGGACTTGAAAGATTCGTTGTGGTG--------+---------+---------+---------+---------+---------+ 1620 GCACTCCGTTACGTCCAAGAACGCAGACACGCTCGTCCTGAACTTTCTAAGCAACACCAC GCAACCTTGTGCCTATCTATCCGAAGCCTCGCTGACTCGCAGAAATAAGGGTCGAGATCC--------+---------+---------+---------+---------+---------+ 1680 CGTTGGAACACGGATAGATAGGCTTCGGAGCGACTGAGCGTCTTTATTCCCAGCTCTAGG ATGAGAGCTTTCTGGGTGGTGAGGCCAGGGCTTGTGAGAACTTCGTGGGAAGATGTGCTT--------+---------+---------+---------+---------+---------+ 1740 TACTCTCGAAAGACCCACCACTCCGGTCCCGAACACTCTTGAAGCACCCTTCTACACGAA GAGCTTCGTCAGCAACTTCACGGAGAGCGCCACCTGATCTAAACATCCGAACATTTTTAG--------+---------+---------+---------+---------+---------+ 1800 CTCGAAGCAGTCGTTGAAGTGCCTCTCGCGGTGGACTAGATTTGTAGGCTTGTAAAAATC CTCGACATGTTCACAGAAATGTTGATAGGTTGAGGCGTGTAAAGGTTCGTTCTGGGAAGA--------+---------+---------+---------+---------+---------+ 1860 GAGCTGTACAAGTGTCTTTACAACTATCCAACTCCGCACATTTCCAAGCAAGACCCTTCT CGAGTAATCATGTCACGCCATGTTAGCGGTCATGTCGCTGCCTCATTGTATTCGGGTGTC--------+---------+---------+---------+---------+---------+ 1920 GCTCATTAGTACAGTGCGGTACAATCGCCAGTACAGCGACGGAGTAACATAAGCCCACAG ACTGTGCCTTCAAACATCAGTCGTGGTTCAGCAGTGTTTGCTGACGTTCGACACACGGAA--------+---------+---------+---------+---------+---------+ 1980 TGACACGGAAGTTTGTAGTCAGCACCAAGTCGTCACAAACGACTGCAAGCTGTGTGCCTT CTCCGGCGAGACTGTCTCGGCAAATGTGACGCACTTTGTATTCATGTGGCAAACCGTTTC--------+---------+---------+---------+---------+---------+ 2040 GAGGCCGCTCTGACAGAGCCGTTTACACTGCGTGAAACATAAGTACACCGTTTGGCAAAG AACGCGGTAATGTGTTTTCTTGTTAAAAAAAAAA--------+---------+---------+---- 2074 TTGCGCCATTACACAAAAGAACAATTTTTTTTTT__________________________________________________________________________ TABLE 11__________________________________________________________________________Nucleotide sequence of the cDNA and amino-acid sequencederived therefrom of the T.gondii antigen P68__________________________________________________________________________ GCCACTGCTGTGTCTGAAGCGTGCCGATGTGTGCGCGTACGCTTACAGAGAGCCTGCAAG--------+---------+---------+---------+---------+---------+ 60 CGGTGACGACACAGACTTCGCACGGCTACACACGCGCATGCGAATGTCTCTCGGACGTTC ACACTGGTTGGAAGACAAAATTTTTCTTCTCAAGAGTTGAGCTTTAGTTTGGTCACTCGC--------+---------+---------+---------+---------+---------+ 120 TGTGACCAACCTTCTGTTTTAAAAAGAAGAGTTCTCAACTCGAAATCAAACCAGTGAGCG CGTTGGTTGTTCTGTGTGCTAGACGTACTCTAACGCAAACCAGTCGAGGAACACACGAAC--------+---------+---------+---------+---------+---------+ 180 GCAACCAACAAGACACACGATCTGCATGAGATTGCGTTTGGTCAGCTCCTTGTGTGCTTG GAGAGAGACGGCAATATCTCCCGTCGCGCTATCATACCGGCAACATGGATTGCGGACAGT--------+---------+---------+---------+---------+---------+ 240 CTCTCTCTGCCGTTATAGAGGGCAGCGCGATAGTATGGCCGTTGTACCTAACGCCTGTCA MetAspCysGlyGlnC GCAGAAGGCAACTGCACGCAGCAGGTGTTCTAGGCTTGTTTGTCACCCTTGCCACAGCAA--------+---------+---------+---------+---------+---------+ 300 CGTCTTCCGTTGACGTGCGTCGTCCACAAGATCCGAACAAACAGTGGGAACGGTGTCGTT ysArgArgGlnLeuHisAlaAlaGlyValLeuGlyLeuPheValThrLeuAlaThrAlaT CCGTAGGATTGAGCCAAAGGGTGCCAGAGCTACCAGAAGTGGAGTCCTTTGATGAAGTAG--------+---------+---------+---------+---------+---------+ 360 GGCATCCTAACTCGGTTTCCCACGGTCTCGATGGTCTTCACCTCAGGAAACTACTTCATC hrValGlyLeuSerGlnArgValProGluLeuProGluvalGluSerPheAspGluValG GCACGGGAGCTCGACGGTCCGGGTCCATTGCGACCCTTCTTCCACAAGACGCTGTTTTAT--------+---------+---------+---------+---------+---------+ 420 CGTGCCCTCGAGCTGCCAGGCCCAGGTAACGCTGGGAAGAAGGTGTTCTGCGACAAAATA lyThrGlyAlaArgArgSerGlySerIleAlaThrLeuLeuProGlnAspAlaValLeuT ATGAGAACTCAGAGGACGTTGCCGTTCCGAGTGATTCAGCATCGACCCCGTCATACTTTC--------+---------+---------+---------+---------+---------+ 480 TACTCTTGAGTCTCCTGCAACGGCAAGGCTCACTAAGTCGTAGCTGGGGCAGTATGAAAG yrGluAsnSerGluAspValAlaValProSerAspSerAlaSerThrProSerTyrPheH ATGTGGAATCTCCAAGTGCTAGTGTGGAAGCCGCGACTGGCGCGGTGGGAGAGGTGGTGC--------+---------+---------+---------+---------+---------+ 540 TACACCTTAGAGGTTCACGATCACACCTTCGGCGCTGACCGCGCCACCCTCTCCACCACG isValGluSerProSerAlaSerValGluAlaAlaThrGlyAlaValGlyGluValValP CGGACTGTGAAGAACGACAGGAACAGGGTGACACGACGTTATCCGATCACGATTTCCATT--------+---------+---------+---------+---------+---------+ 600 GCCTGACACTTCTTGCTGTCCTTGTCCCACTGTGCTGCAATAGGCTAGTGCTAAAGGTAA roAspCysGluGluArgGlnGluGlnGlyAspThrThrLeuSerAspHisAspPheHisS CAGGTGGAACTGAACAGGAGGGTTTGCCGGAAACAGAGGTGGCGCATCAGCATGAGACAG--------+---------+---------+---------+---------+---------+ 660 GTCCACCTTGACTTGTCCTCCCAAACGGCCTTTGTCTCCACCGCGTAGTCGTACTCTGTC erGlyGlyThrGluGlnGluGlyLeuProGluThrGluValAlaHisGlnHisGluThrG AAGAACAGTACGGGACTGAAGGGATGCCCCCCCCTGTTCTGCCACCTGCACCGGTAGTCC--------+---------+---------+---------+---------+---------+ 720 TTCTTGTCATGCCCTGACTTCCCTACGGGGGGGGACAAGACGGTGGACGTGGCCATCAGG luGluGlnTyrGlyThrGluGlyMetProProProValLeuProProAlaProValValH ATCCGCGTTTTATTGCAGTACCAGGGCCGTCGGTGCCTGTTCCATTTTTCAGTTTGCCAG--------+---------+---------+---------+---------+---------+ 780 TAGGCGCAAAATAACGTCATGGTCCCGGCAGCCACGGACAAGGTAAAAAGTCAAACGGTC isProArgPheIleAlaValProGlyProSerValProValProPhePheSerLeuProA ACATCCACCCGGATCAGGTTGTGTATATTCTAAGGGTTCAGGGATCTGGGGACTTCGACA--------+---------+---------+---------+---------+---------+ 840 TGTAGGTGGGCCTAGTCCAACACATATAAGATTCCCAAGTCCCTAGACCCCTGAAGCTGT spIleHisProAspGlnValValTyrIleLeuArgValGlnGlySerGlyAspPheAspI TCAGTTTCGAAGTTGGCCGAGCTGTGAAGCAGTTGGAAGCCATCAAGAAAGCATACAGAG--------+---------+---------+---------+---------+---------+ 900 AGTCAAAGCTTCAACCGGCTCGACACTTCGTCAACCTTCGGTAGTTCTTTCGTATGTCTC leSerPheGluValGlyArgAlaValLysGlnLeuGluAlaIleLysLysAlaTyrArgG AAGCCACCGGGAAGCTAGAAGCAGACGAGCTTGAGTCAGAAAGGGGACCTGCTGTTTCAC--------+---------+---------+---------+---------+---------+ 960 TTCGGTGGCCCTTCGATCTTCGTCTGCTCGAACTCAGTCTTTCCCCTGGACGACAAAGTG luAlaThrGlyLysLeuGluAlaAspGluLeuGluSerGluArgGlyProAlaValSerP CTCGACGAAGGCTGGTTGACCTGATCAAAGATAACCAGCGACGACTCAGGGCGGCGCTTC--------+---------+---------+---------+---------+---------+ 1020 GAGCTGCTTCCGACCAACTGGACTAGTTTCTATTGGTCGCTGCTGAGTCCCGCCGCGAAG roArgArgArgLeuValAspLeuIleLysAspAsnG1nArgArgLeuArgAlaAlaLeuG AGAAGATAAAGATACAGAAAAAGTTGGAGGAGATTGATGACTTACTTCAGCTGACACGCG--------+---------+---------+---------+---------+---------+ 1080 TCTTCTATTTCTATGTCTTTTTCAACCTCCTCTAACTACTGAATGAAGTCGACTGTGCGC lnLysIleLysIleGlnLysLysLeuGluGluIleAspAspLeuLeuGlnLeuThrArgA CACTGAAGGCCATGGATGCCCGTCTGAGAGCCTGCCAGGATATGGCACCGATTGAGGAGG--------+---------+---------+---------+---------+---------+ 1140 GTGACTTCCGGTACCTACGGGCAGACTCTCGGACGGTCCTATACCGTGGCTAACTCCTCC laLeuLysAlaMetAspAlaArgLeuArgAlaCysGlnAspMetAlaProIleGluGluA CGCTGTGTCACAAGACGAAGGCGTTTGGAGAAATGGTGTCCCAGAAAGCCAAGGAAATTC--------+---------+---------+---------+---------+---------+ 1200 GCGACACAGTGTTCTGCTTCCGCAAACCTCTTTACCACAGGGTCTTTCGGTTCCTTTAAG laLeuCysHisLysThrLysAlaPheGlyGluMetValSerGlnLysAlaLysGluIleA GGGAGAAAGCGGCGTCCTTGTCTTCATTGTTAGGTGTCGATGCTGTCGAAAAAGAATTGC--------+---------+---------+---------+---------+---------+ 1260 CCCTCTTTCGCCGCAGGAACAGAAGTAACAATCCACAGCTACGACAGCTTTTTCTTAACG rgGluLysAlaAlaSerLeuSerSerLeuLeuGlyValAspAlaValGluLysGluLeuA GGCGTGTCGAACCGGAACATGAAGATAACACCAGAGTTGAAGCCAGGGTAGAGGAATTGC--------+---------+---------+---------+---------+---------+ 1320 CCGCACAGCTTGGCCTTGTACTTCTATTGTGGTCTCAACTTCGGTCCCATCTCCTTAACG rgArgValGluProGluHisGluAspAsnThrArgValGluAlaArgValGluGluLeuG AGAAGGCGCTGGAGAAGGCCGCGTCTGAGGCAAAGCAGCTCGTGGGGACCGCAGCAGGCG--------+---------+---------+---------+---------+---------+ 1380 TCTTCCGCGACCTCTTCCGGCGCAGACTCCGTTTCGTCGAGCACCCCTGGCGTCGTCCGC lnLysAlaLeuGluLysAlaAlaSerGlaAlaLysGlnLeuValGlyThrAlaAlaGlyG AAATAGAGGAAGGAGTAAAAGCGGATACTCAGGCTGTGCAAGATAGCTCGAAAGACGTGT--------+---------+---------+---------+---------+---------+ 1440 TTTATCTCCTTCCTCATTTTCGCCTATGAGTCCGACACGTTCTATCGAGCTTTCTGCACA luIleGluGluGlyValLysAlaAspThrGlnAlaValGlnAspSerSerLysAspValL TGACGAAGAGTCCAGTTGCGCTCGTGGAAGCCTTTAAAGCGATCCAGAGGGCTCTTCTTG--------+---------+---------+---------+---------+---------+ 1500 ACTGCTTCTCAGGTCAACGCGAGCACCTTCGGAAATTTCGCTAGGTCTCCCGAGAAGAAC euThrLysSerProValAlaLeuValGluAlaPheLysAlaIleGlnArgAlaLeuLeuG AGGCGAAGACAAAGGAACTAGTAGAGCCTACGTCTAAAGAAGCGGAGGAAGCTCGTCAGA--------+---------+---------+---------+---------+---------+ 1560 TCCGCTTCTGTTTCCTTGATCATCTCGGATGCAGATTTCTTCGCCTCCTTCGAGCAGTCT luAlaLysThrLysGluLeuValGluProThrSerLysGluAlaGluGluAlaArgGlnI TCTTAGCGGAACAGGCAGCTTGATTTCCCAAGGATGCAGTTAAAGATGGGGATGCATGAT--------+---------+---------+---------+---------+---------+ 1620 AGAATCGCCTTGTCCGTCGAACTAAAGGGTTCCTACGTCAATTTCTACCCCTACGTACTA leLeuAlaGluGlnAlaAla AGGTAGCGCGCCCATTATCCCAATCCTTTAGCCGTCTACCGTGACGTGGATCATTATAGG--------+---------+---------+---------+---------+---------+ 1680 TCCATCGCGCGGGTAATAGGGTTAGGAAATCGGCAGATGGCACTGCACCTAGTAATATCC GGAAACAAGCATTAGCAGAATGATCGTGTATCGCGGAACACACGCATATCCGCACCAGTT--------+---------+---------+---------+---------+---------+ 1740 CCTTTGTTCGTAATCGTCTTACTAGCACATAGCGCCTTGTGTGCGTATAGGCGTGGTCAA TTTCTAACGTATGGTGAATGGGTTCAAGTCTGGGTTCAAGGCGCAGTGTCTATGCAACAG--------+---------+---------+---------+---------+---------+ 1800 AAAGATTGCATACCACTTACCCAAGTTCAGACCCAAGTTCCGCGTCACAGATACGTTGTC CGCCGGTTTCTGCCCTTCGTTTTTGCACATGTGCACAGGTATGTACAGTGTTTATGTATA--------+---------+---------+---------+---------+---------+ 1860 GCGGCCAAAGACGGGAAGCAAAAACGTGTACACGTGTCCATACATGTCACAAATACATAT TGGGGCAGTGTGCGCTTCGTCAATGATGTACAGAAAAAAAAAAAAAAAA--------+---------+---------+---------+--------- 1909 ACCCCGTCACAGCGAAGCAGTTACTACATGTCTTTTTTTTTTTTTTTTT__________________________________________________________________________ TABLE 12______________________________________Western blot - EvaluationT. gondii protein r- P29 r- P35 r- P66 r- P68______________________________________Expression plasmid pPS29 pPS76 pPS61 pPS34IgG 5/16 25/26 21/31 27/31IgM 0/21 2/21 17/21 0/21______________________________________ TABLE 13______________________________________Comparison of recombinant and nonrecombinantT. gondii ELISA______________________________________ ##STR1##______________________________________ ##STR2## - __________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 20- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1179 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- CATATACTGC ACTGACTTCG ACACCATGGA GCAAAGGCTG CCAATTATTC TA - #CTTGTTCT 60- CTCTGTGTTC TTCAGTTCAA CCCCAAGCGC CGCCCTTTCG AGCCACAATG GA - #GTCCCCGC 120- TTATCCATCG TATGCACAGG TATCGCTCTC TTCCAACGGC GAGCCACGGC AC - #AGGGGCAT 180- ACGCGGCAGC TTCCTCATGT CCGTAAAGCC ACACGCAAAC GCTGATGACT TC - #GCCTCCGA 240- CGACAACTAC GAACCGCTGC CGAGTTTCGT GGAAGCTCCT GTCAGAGGCC CG - #GACCAAGT 300- CCCTGCCAGA GGAGAAGCTG CTCTTGTCAC AGAGGAGACT CCAGCGCAAC AG - #CCGGCGGT 360- GGCTCTAGGC AGTGCAGAAG GGGAGGGGAC TCCACCTACT GAATCCGCCT CC - #GAAAATTC 420- TGAAGATGAT GACACGTTTC ACGATGCCCT CCAAGAGCTT CCAGAGGATG GC - #CTCGAAGT 480- GCGCCCACCA AATGCACAGG AGCTGCCCCC ACCAAATGTA CAGGAGCTGC CC - #CCACCAAA 540- TGTACAGGAG CTGCCCCCAC CAACTGAACA GGAGCTGCCC CCACCAACTG AA - #CAGGAGCT 600- GCCCCCACCA ACTGAACAGG AGCTGCCCCC ACCAACTGAA CAGGAGCTAG CC - #CCATCAAC 660- TGAACAGGAG CTGCCCCCAC CAGTGGGCGA AGGTCAACGT CTGCAAGTCC CT - #GGGGAACA 720- TGGGCCACAG GGGCCCCCAT ACGATGATCA GCAGCTGCTT TTAGAGCCTA CG - #GAAGAGCA 780- ACAGGAGGGC CCTCAGGAGC CGCTGCCACC GCCGCCGCCC CCGACTCGGG GC - #GAACAACC 840- CGAAGGACAG CAGCCGCAGG GACCAGTTCG TCAAAATTTT TTTCGTCGGG CG - #TTGGGGGC 900- CGCAAGAAGC CGATTCGGAG GTGCACGACG CCATGTCAGT GGGGTGTTCC GA - #AGAGTCAG 960- AGGTGGTTTG AACCGTATAG TAGGTGGAGT GAGGAGTGGT TTCAGGCGTG CA - #AGAGAAGG1020- TGTCGTTGGG GGAGTCCGTC GTTTAACAAG TGGTGCCAGT CTGGGTCTCG GT - #CGTGTAGG1080- AGAAGGTTTA GGTAGGAGTT TCTATCGTGT AAGAGGAGCT GTCAGTAGCG GT - #CGTAGGCG1140# 1179 AGCA ATGTAAGAGA AAGATTCGT- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 392 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Ile Tyr Cys Thr Asp Phe Asp Thr Met Glu Gl - #n Arg Leu Pro Ile Ile# 15- Leu Leu Val Leu Ser Val Phe Phe Ser Ser Th - #r Pro Ser Ala Ala Leu# 30- Ser Ser His Asn Gly Val Pro Ala Tyr Pro Se - #r Tyr Ala Gln Val Ser# 45- Leu Ser Ser Asn Gly Glu Pro Arg His Arg Gl - #y Ile Arg Gly Ser Phe# 60- Leu Met Ser Val Lys Pro His Ala Asn Ala As - #p Asp Phe Ala Ser Asp#80- Asp Asn Tyr Glu Pro Leu Pro Ser Phe Val Gl - #u Ala Pro Val Arg Gly# 95- Pro Asp Gln Val Pro Ala Arg Gly Glu Ala Al - #a Leu Val Thr Glu Glu# 110- Thr Pro Ala Gln Gln Pro Ala Val Ala Leu Gl - #y Ser Ala Glu Gly Glu# 125- Gly Thr Pro Pro Thr Glu Ser Ala Ser Glu As - #n Ser Glu Asp Asp Asp# 140- Thr Phe His Asp Ala Leu Gln Glu Leu Pro Gl - #u Asp Gly Leu Glu Val145 1 - #50 1 - #55 1 -#60- Arg Pro Pro Asn Ala Gln Glu Leu Pro Pro Pr - #o Asn Val Gln Glu Leu# 175- Pro Pro Pro Asn Val Gln Glu Leu Pro Pro Pr - #o Thr Glu Gln Glu Leu# 190- Pro Pro Pro Thr Glu Gln Glu Leu Pro Pro Pr - #o Thr Glu Gln Glu Leu# 205- Pro Pro Pro Thr Glu Gln Glu Leu Ala Pro Se - #r Thr Glu Gln Glu Leu# 220- Pro Pro Pro Val Gly Glu Gly Gln Arg Leu Gl - #n Val Pro Gly Glu His225 2 - #30 2 - #35 2 -#40- Gly Pro Gln Gly Pro Pro Tyr Asp Asp Gln Gl - #n Leu Leu Leu Glu Pro# 255- Thr Glu Glu Gln Gln Glu Gly Pro Gln Glu Pr - #o Leu Pro Pro Pro Pro# 270- Pro Pro Thr Arg Gly Glu Gln Pro Glu Gly Gl - #n Gln Pro Gln Gly Pro# 285- Val Arg Gln Asn Phe Phe Arg Arg Ala Leu Gl - #y Ala Ala Arg Ser Arg# 300- Phe Gly Gly Ala Arg Arg His Val Ser Gly Va - #l Phe Arg Arg Val Arg305 3 - #10 3 - #15 3 -#20- Gly Gly Leu Asn Arg Ile Val Gly Gly Val Ar - #g Ser Gly Phe Arg Arg# 335- Ala Arg Glu Gly Val Val Gly Gly Val Arg Ar - #g Leu Thr Ser Gly Ala# 350- Ser Leu Gly Leu Gly Arg Val Gly Glu Gly Le - #u Gly Arg Ser Phe Tyr# 365- Arg Val Arg Gly Ala Val Ser Ser Gly Arg Ar - #g Arg Ala Ala Asp Gly# 380- Ala Ser Asn Val Arg Glu Arg Phe385 3 - #90- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 921 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- CTGAACAGGA GGGTTTGCCG GAAACAGAGG TGGCGCATCA GCATGAGACA GA - #AGAACAGT 60- ACGGGACTGA AGGGATGCCC CCCCCTGTTC TGCCACCTGC ACCGGTAGTC CA - #TCCGCGTT 120- TTATTGCAGT ACCAGGGCCG TCGGTGCCTG TTCCATTTTT CAGTTTGCCA GA - #CATCCACC 180- CGGATCAGGT TGTGTATATT CTAAGGGTTC AGGGATCTGG GGACTTCGAC AT - #CAGTTTCG 240- AAGTTGGCCG AGCTGTGAAG CAGTTGGAAG CCATCAAGAA AGCATACAGA GA - #AGCCACCG 300- GGAAGCTAGA AGCAGACGAG CTTGAGTCAG AAAGGGGACC TGCTGTTTCA CC - #TCGACGAA 360- GGCTGGTTGA CCTGATCAAA GATAACCAGC GACGACTCAG GGCGGCGCTT CA - #GAAGATAA 420- AGATACAGAA AAAGTTGGAG GAGATTGATG ACTTACTTCA GCTGACACGC GC - #ACTGAAGG 480- CCATGGATGC CCGTCTGAGA GCCTGCCAGG ATATGGCACC GATTGAGGAG GC - #GCTGTGTC 540- ACAAGACGAA GGCGTTTGGA GAAATGGTGT CCCAGAAAGC CAAGGAAATT CG - #GGAGAAAG 600- CGGCGTCCTT GTCTTCATTG TTAGGTGTCG ATGCTGTCGA AAAAGAATTG CG - #GCGTGTCG 660- AACCGGAACA TGAAGATAAC ACCAGAGTTG AAGCCAGGGT AGAGGAATTG CA - #GAAGGCGC 720- TGGAGAAGGC CGCGTCTGAG GCAAAGCAGC TCGTGGGGAC CGCAGCAGGC GA - #AATAGAGG 780- AAGGAGTAAA AGCGGATACT CAGGCTGTGC AAGATAGCTC GAAAGACGTG TT - #GACGAAGA 840- GTCCAGTTGC GCTCGTGGAA GCCTTTAAAG CGATCCAGAG GGCTCTTCTT GA - #GGCGAAGA 900# 921CT A- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 306 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- Glu Gln Glu Gly Leu Pro Glu Thr Glu Val Al - #a His Gln His Glu Thr# 15- Glu Glu Gln Tyr Gly Thr Glu Gly Met Pro Pr - #o Pro Val Leu Pro Pro# 30- Ala Pro Val Val His Pro Arg Phe Ile Ala Va - #l Pro Gly Pro Ser Val# 45- Pro Val Pro Phe Phe Ser Leu Pro Asp Ile Hi - #s Pro Asp Gln Val Val# 60- Tyr Ile Leu Arg Val Gln Gly Ser Gly Asp Ph - #e Asp Ile Ser Phe Glu#80- Val Gly Arg Ala Val Lys Gln Leu Glu Ala Il - #e Lys Lys Ala Tyr Arg# 95- Glu Ala Thr Gly Lys Leu Glu Ala Asp Glu Le - #u Glu Ser Glu Arg Gly# 110- Pro Ala Val Ser Pro Arg Arg Arg Leu Val As - #p Leu Ile Lys Asp Asn# 125- Gln Arg Arg Leu Arg Ala Ala Leu Gln Lys Il - #e Lys Ile Gln Lys Lys# 140- Leu Glu Glu Ile Asp Asp Leu Leu Gln Leu Th - #r Arg Ala Leu Lys Ala145 1 - #50 1 - #55 1 -#60- Met Asp Ala Arg Leu Arg Ala Cys Gln Asp Me - #t Ala Pro Ile Glu Glu# 175- Ala Leu Cys His Lys Thr Lys Ala Phe Gly Gl - #u Met Val Ser Gln Lys# 190- Ala Lys Glu Ile Arg Glu Lys Ala Ala Ser Le - #u Ser Ser Leu Leu Gly# 205- Val Asp Ala Val Glu Lys Glu Leu Arg Arg Va - #l Glu Pro Glu His Glu# 220- Asp Asn Thr Arg Val Glu Ala Arg Val Glu Gl - #u Leu Gln Lys Ala Leu225 2 - #30 2 - #35 2 -#40- Glu Lys Ala Ala Ser Glu Ala Lys Gln Leu Va - #l Gly Thr Ala Ala Gly# 255- Glu Ile Glu Glu Gly Val Lys Ala Asp Thr Gl - #n Ala Val Gln Asp Ser# 270- Ser Lys Asp Val Leu Thr Lys Ser Pro Val Al - #a Leu Val Glu Ala Phe# 285- Lys Ala Ile Gln Arg Ala Leu Leu Glu Ala Ly - #s Thr Lys Glu Leu Val# 300- Glu Pro305- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 226 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- GCCGGAACTA ACAGAGGAGC AACAGAGAGG CGACGAACCC CTAACCACCG GC - #CAGAATGT 60- GGGCACTGTG TTAGGCTTCG CAGCGCTTGC TGCTGCCGCA GCGTTCCTTG GC - #ATGGGTCT 120- CACGAGGACG TACCGACATT TTTCCCCACG CAAAAACAGA TCACGGCAGC CT - #GCACTCGA 180# 226CAG GCGAAGATGG GGAGGATGCC CGCCAG- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 75 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Pro Glu Leu Thr Glu Glu Gln Gln Arg Gly As - #p Glu Pro Leu Thr Thr# 15- Gly Gln Asn Val Gly Thr Val Leu Gly Phe Al - #a Ala Leu Ala Ala Ala# 30- Ala Ala Phe Leu Gly Met Gly Leu Thr Arg Th - #r Tyr Arg His Phe Ser# 45- Pro Arg Lys Asn Arg Ser Arg Gln Pro Ala Le - #u Glu Gln Glu Val Pro# 60- Glu Ser Gly Glu Asp Gly Glu Asp Ala Arg Gl - #n#75- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 333 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- CCGTTGCTGT CGGGGTGCTA TCTTCTCCCA CCTTTTATCA GTTAAGTTGT AC - #AGTGAGTG 60- TCAGCTTGTT TCGACACGTC TGTATAGACG CAACTCGGTT TGCTTGTGTT GT - #TTGGTGGC 120- TGGCCAAATC AAAGGCTATT CATTTTTCAC TTGCTGTTGT TCTTTGAAGA AA - #TCAAGCAA 180- GATGGTGCGT GTGAGCGCTA TTGTCGGAGC TGCTGCATCG GTGTTCGTGT GC - #CTGTCTGC 240- CGGCGCTTAC GCTGCCGAAG GCGGCGACAA CCAGTCGAGC GCCGTCTCAG AT - #CGGGCGTC 300# 333 AGTG GAGGGACAGG GCA- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 110 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Arg Cys Cys Arg Gly Ala Ile Phe Ser His Le - #u Leu Ser Val Lys Leu# 15- Tyr Ser Glu Cys Gln Leu Val Ser Thr Arg Le - #u Tyr Arg Arg Asn Ser# 30- Val Cys Leu Cys Cys Leu Val Ala Gly Gln Il - #e Lys Gly Tyr Ser Phe# 45- Phe Thr Cys Cys Cys Ser Leu Lys Lys Ser Se - #r Lys Met Val Arg Val# 60- Ser Ala Ile Val Gly Ala Ala Ala Ser Val Ph - #e Val Cys Leu Ser Ala#80- Gly Ala Tyr Ala Ala Glu Gly Gly Asp Asn Gl - #n Ser Ser Ala Val Ser# 95- Asp Arg Ala Ser Leu Phe Gly Leu Leu Ser Gl - #y Gly Thr Gly# 110- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 355 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:- CAGTTTCGCG CGTCCCGTTT CCACGGACAA AATGGCAATG AAATACGTCG CT - #GCTTACCT 60- GATGGTGGTG CTGTCGGGAA CCGACACTCC GACCAAGAAG CAGGTTGAGA AA - #ACCCTCTC 120- CTCTGTGGGT ATTGATGTTG AAGACGACAT CATGGACACC TTCTTCAAAG CT - #GTCGAAGG 180- AAAGACCCCC CACGAGCTGA TTGCCGCGGG TATGGAGAAG CTCCAGAAGG TA - #CCTTCTGG 240- TGGTGTCGCT GCTGCTGCTG CTCCTGCTGC TGGCGCTGCC GATGCTGGTG CG - #GGTGCTGC 300- TGCTGCGAAG AAGGAGGAGG AAAAGAAGGA GGAAGAGGAG GAGGAAGACG AC - #ATG 355- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 118 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:- Ser Phe Ala Arg Pro Val Ser Thr Asp Lys Me - #t Ala Met Lys Tyr Val# 15- Ala Ala Tyr Leu Met Val Val Leu Ser Gly Th - #r Asp Thr Pro Thr Lys# 30- Lys Gln Val Glu Lys Thr Leu Ser Ser Val Gl - #y Ile Asp Val Glu Asp# 45- Asp Ile Met Asp Thr Phe Phe Lys Ala Val Gl - #u Gly Lys Thr Pro His# 60- Glu Leu Ile Ala Ala Gly Met Glu Lys Leu Gl - #n Lys Val Pro Ser Gly#80- Gly Val Ala Ala Ala Ala Ala Pro Ala Ala Gl - #y Ala Ala Asp Ala Gly# 95- Ala Gly Ala Ala Ala Ala Lys Lys Glu Glu Gl - #u Lys Lys Glu Glu Glu# 110- Glu Glu Glu Asp Asp Met 115- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 164 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- GCCACAGCCA GAGATACCGC CTGTTCATCG GCCGCCGCCT CCGGGTTTCC GT - #CCCGAAGT 60- GGCTCCCGTG CCCCCGTATC CAGTGGGCAC TCCAACGGGC ATGCCCCAGC CG - #GAGATACC 120#164 TTCC CCTACGTTAC GACAACCACG ACAG- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 54 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Pro Gln Pro Glu Ile Pro Pro Val His Arg Pr - #o Pro Pro Pro Gly Phe# 15- Arg Pro Glu Val Ala Pro Val Pro Pro Tyr Pr - #o Val Gly Thr Pro Thr# 30- Gly Met Pro Gln Pro Glu Ile Pro Ala Val Hi - #s His Pro Phe Pro Tyr# 45- Val Thr Thr Thr Thr Thr 50- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 250 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:- ATATATGTGT CTCGTGCTTG AGTGTGTTCT TTGTATGATC AAAACTCGTT AA - #AATGCGCA 60- CGTTACCGCA TGGGTAGTAG TTCGAGACAG CTTGTGTGTA CCTGAGGGGC CG - #CGTGTTGC 120- CAAAAGTGCC TAGTCTTACA CGGCCGACAA GAGGGTTCCT CGGTTCTTCT CT - #GCGTTCTT 180- CCTTCTCCCA TCCGATTCTT CAAGTTCTGA ACAAATCTGT CGTGTCTCGA CT - #GATGTGCG 240# 250- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 246 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:- GGAATTCTTG TTACGCGGTC AGATGTTTCT TGAGTAGTGA ATCAAAATGT AT - #TATGGTGT 60- AATCCTGTCA GTTTTATACG TATTGTCATA CGTCCACGCA TCTCACGTAC GG - #GCGCGAAC 120- GCAGCAAGTG ACGAGAGATC ATCCCACTCG TTTGGTGACG CTGCAAAATA CA - #AGTGTATT 180- ATACGGTCAG TCGGCTCTAC AACATTCAAA ACGAGTTGTC TCGCTTCAAC CA - #CAAAGCGC 240# 246- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1092 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- CAGTTTCCGC GCTGTAGTAA GATGGCTTTA CCATTGCGTG TTTCGGCCAC GG - #TGTTCGTG 60- GTCTTCGCTG TCTTTGGTGT AGCTCGCGCC ATGAACGGTC CTTTGAGTTA TC - #ATCCAAGC 120- AGTTACGGAG CGTCGTATCC GAATCCGAGT AATCCTCTGC ATGGAATGCC CA - #AGCCAGAG 180- AACCCGGTGA GACCGCCTCC TCCCGGTTTC CATCCAAGCG TTATTCCCAA TC - #CCCCGTAC 240- CCGCTGGGCA CTCCAGCGAG CATGCCACAG CCAGAGGTTC CGCCACTTCA GC - #ATCCCCCG 300- CCAACGGGTT CCCCTCCCGC GGCCGCTCCC CAGCCTCCAT ATCCAGTGGG TA - #CTCCAGTA 360- ATGCCACAGC CAGAGATACC GCCTGTTCAT CGGCCGCCGC CTCCGGGTTT CC - #GTCCCGAA 420- GTGGCTCCCG TGCCCCCGTA TCCAGTGGGC ACTCCAACGG GCATGCCCCA GC - #CGGAGATA 480- CCGGCAGTTC ACCATCCGTT CCCCTACGTT ACGACAACCA CGACAGCTGC TC - #CTCGTGTG 540- CTGGTTTATA AGATTCCCTA TGGAGGCGCT GCACCCCCCC GTGCTCCTCC AG - #TGCCACCC 600- CGTATGGGCC CGAGTGATAT CAGCACTCAC GTGCGGGGTG CAATCCGGCG TC - #AACCCGGT 660- ACCACCACCA CCACTACTTC CCGCAAACTA CTATTCAGGA CAGCGGTAGT GG - #CTGCAATG 720- GCAGCAGCCT TGATAACCCT GTTCAGACAA AGACCTGTGT TCATGGAGGG GG - #TACGGATG 780- TTTCCAAATC TCCACTACAG ATTCACCGTA ACGACGCAGA ATTAAATTTC CG - #GTTGACGA 840- ATATAGAAGT CACTTATACA GTGGGTACAC GACCTTCGTG GCGTCCACAC CT - #TGTTTCCG 900- TTCCGGTCAC AGGTTGTGTC TACAAACGAA CACGGTGGTA TGTGCTGTAG AC - #TCAGGGGT 960- GGGAGGAGCG CTGTAGGGCC TTCTGGAGAG CTCTCAATGT GCGCTATCCG CT - #TATATTCG1020- TGCAGCGTTA TCCTCGTGAG GAGCGTCGAT TGTGTCGTGC CCAGTCTCGC CG - #GACTCGAA1080# 1092- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 267 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:- Met Ala Leu Pro Leu Arg Val Ser Ala Thr Va - #l Phe Val Val Phe Ala# 15- Val Phe Gly Val Ala Arg Ala Met Asn Gly Pr - #o Leu Ser Tyr His Pro# 30- Ser Ser Tyr Gly Ala Ser Tyr Pro Asn Pro Se - #r Asn Pro Leu His Gly# 45- Met Pro Lys Pro Glu Asn Pro Val Arg Pro Pr - #o Pro Pro Gly Phe His# 60- Pro Ser Val Ile Pro Asn Pro Pro Tyr Pro Le - #u Gly Thr Pro Ala Ser#80- Met Pro Gln Pro Glu Val Pro Pro Leu Gln Hi - #s Pro Pro Pro Thr Gly# 95- Ser Pro Pro Ala Ala Ala Pro Gln Pro Pro Ty - #r Pro Val Gly Thr Pro# 110- Val Met Pro Gln Pro Glu Ile Pro Pro Val Hi - #s Arg Pro Pro Pro Pro# 125- Gly Phe Arg Pro Glu Val Ala Pro Val Pro Pr - #o Tyr Pro Val Gly Thr# 140- Pro Thr Gly Met Pro Gln Pro Glu Ile Pro Al - #a Val His His Pro Phe145 1 - #50 1 - #55 1 -#60- Pro Tyr Val Thr Thr Thr Thr Thr Ala Ala Pr - #o Arg Val Leu Val Tyr# 175- Lys Ile Pro Tyr Gly Gly Ala Ala Pro Pro Ar - #g Ala Pro Pro Val Pro# 190- Pro Arg Met Gly Pro Ser Asp Ile Ser Thr Hi - #s Val Arg Gly Ala Ile# 205- Arg Arg Gln Pro Gly Thr Thr Thr Thr Thr Th - #r Ser Arg Lys Leu Leu# 220- Phe Arg Thr Ala Val Val Ala Ala Met Ala Al - #a Ala Leu Ile Thr Leu225 2 - #30 2 - #35 2 -#40- Phe Arg Gln Arg Pro Val Phe Met Glu Gly Va - #l Arg Met Phe Pro Asn# 255- Leu His Tyr Arg Phe Thr Val Thr Thr Gln As - #n# 265- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2074 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:- TTGCTGTCGC CGTTGCTGTC GCATATACTG CACTGACTTC GACACCATGG AG - #CAAAGGCT 60- GCCAATTATT CTACTTGTTC TCTCTGTGTT CTTCAGTTCA ACCCCAAGCG CC - #GCCCTTTC 120- GAGCCACAAT GGAGTCCCCG CTTATCCATC GTATGCACAG GTATCGCTCT CT - #TCCAACGG 180- CGAGCCACGG CACAGGGGCA TACGCGGCAG CTTCCTCATG TCCGTAAAGC CA - #CACGCAAA 240- CGCTGATGAC TTCGCCTCCG ACGACAACTA CGAACCGCTG CCGAGTTTCG TG - #GAAGCTCC 300- TGTCAGAGGC CCGGACCAAG TCCCTGCCAG AGGAGAAGCT GCTCTTGTCA CA - #GAGGAGAC 360- TCCAGCGCAA CAGCCGGCGG TGGCTCTAGG CAGTGCAGAA GGGGAGGGGA CT - #CCACCTAC 420- TGAATCCGCC TCCGAAAATT CTGAAGATGA TGACACGTTT CACGATGCCC TC - #CAAGAGCT 480- TCCAGAGGAT GGCCTCGAAG TGCGCCCACC AAATGCACAG GAGCTGCCCC CA - #CCAAATGT 540- ACAGGAGCTG CCCCCACCAA ATGTACAGGA GCTGCCCCCA CCAACTGAAC AG - #GAGCTGCC 600- CCCACCAACT GAACAGGAGC TGCCCCCACC AACTGAACAG GAGCTGCCCC CA - #CCAACTGA 660- ACAGGAGCTA GCCCCATCAA CTGAACAGGA GCTGCCCCCA CCAGTGGGCG AA - #GGTCAACG 720- TCTGCAAGTC CCTGGGGAAC ATGGGCCACA GGGGCCCCCA TACGATGATC AG - #CAGCTGCT 780- TTTAGAGCCT ACGGAAGAGC AACAGGAGGG CCCTCAGGAG CCGCTGCCAC CG - #CCGCCGCC 840- CCCGACTCGG GGCGAACAAC CCGAAGGACA GCAGCCGCAG GGACCAGTTC GT - #CAAAATTT 900- TTTTCGTCGG GCGTTGGGGG CCGCAAGAAG CCGATTCGGA GGTGCACGAC GC - #CATGTCAG 960- TGGGGTGTTC CGAAGAGTCA GAGGTGGTTT GAACCGTATA GTAGGTGGAG TG - #AGGAGTGG1020- TTTCAGGCGT GCAAGAGAAG GTGTCGTTGG GGGAGTCCGT CGTTTAACAA GT - #GGTGCCAG1080- TCTGGGTCTC GGTCGTGTAG GAGAAGGTTT AGGTAGGAGT TTCTATCGTG TA - #AGAGGAGC1140- TGTCAGTAGC GGTCGTAGGC GTGCAGCAGA TGGTGCCAGC AATGTAAGAG AA - #AGATTCGT1200- TGCCGCAGGC GGGAGAGTCA GAGACGCTTT CGGCGCGGGA TTGACGCGCC TC - #CGCAGGCG1260- CGGCAGAACT AATGGCGAGG AGGGCAGGCC CCTACTGGGC GAAGGAAGAG AG - #CAGGATGA1320- TGGATCGCAA TAATACGGGC AGCATGCTGC TGGATTCGGC GAAGACGACC GT - #TTCTCGTA1380- AACGACAGCG GGTCCTCCGA AGTTAAGAAA CCCGGTAAAC GTGTGTGCCG TA - #ACGGTGAT1440- CGAGTTTGCA GATGGTTCCT TGTGTACCAC GTGGCTTCTC GAGACCAATC GT - #GCTTTGTT1500- AGGGTCTAGT AGTTCGGACA GGATTTTATT GAACTGCAGG AATGCTTGCA GA - #AGAGAAGC1560- CGTGAGGCAA TGCAGGTTCT TGCGTCTGTG CGAGCAGGAC TTGAAAGATT CG - #TTGTGGTG1620- GCAACCTTGT GCCTATCTAT CCGAAGCCTC GCTGACTCGC AGAAATAAGG GT - #CGAGATCC1680- ATGAGAGCTT TCTGGGTGGT GAGGCCAGGG CTTGTGAGAA CTTCGTGGGA AG - #ATGTGCTT1740- GAGCTTCGTC AGCAACTTCA CGGAGAGCGC CACCTGATCT AAACATCCGA AC - #ATTTTTAG1800- CTCGACATGT TCACAGAAAT GTTGATAGGT TGAGGCGTGT AAAGGTTCGT TC - #TGGGAAGA1860- CGAGTAATCA TGTCACGCCA TGTTAGCGGT CATGTCGCTG CCTCATTGTA TT - #CGGGTGTC1920- ACTGTGCCTT CAAACATCAG TCGTGGTTCA GCAGTGTTTG CTGACGTTCG AC - #ACACGGAA1980- CTCCGGCGAG ACTGTCTCGG CAAATGTGAC GCACTTTGTA TTCATGTGGC AA - #ACCGTTTC2040# 2074 TTCT TGTTAAAAAA AAAA- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 428 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- Met Glu Gln Arg Leu Pro Ile Ile Leu Leu Va - #l Leu Ser Val Phe Phe# 15- Ser Ser Thr Pro Ser Ala Ala Leu Ser Ser Hi - #s Asn Gly Val Pro Ala# 30- Tyr Pro Ser Tyr Ala Gln Val Ser Leu Ser Se - #r Asn Gly Glu Pro Arg# 45- His Arg Gly Ile Arg Gly Ser Phe Leu Met Se - #r Val Lys Pro His Ala# 60- Asn Ala Asp Asp Phe Ala Ser Asp Asp Asn Ty - #r Glu Pro Leu Pro Ser#80- Phe Val Glu Ala Pro Val Arg Gly Pro Asp Gl - #n Val Pro Ala Arg Gly# 95- Glu Ala Ala Leu Val Thr Glu Glu Thr Pro Al - #a Gln Gln Pro Ala Val# 110- Ala Leu Gly Ser Ala Glu Gly Glu Gly Thr Pr - #o Pro Thr Glu Ser Ala# 125- Ser Glu Asn Ser Glu Asp Asp Asp Thr Phe Hi - #s Asp Ala Leu Gln Glu# 140- Leu Pro Glu Asp Gly Leu Glu Val Arg Pro Pr - #o Asn Ala Gln Glu Leu145 1 - #50 1 - #55 1 -#60- Pro Pro Pro Asn Val Gln Glu Leu Pro Pro Pr - #o Asn Val Gln Glu Leu# 175- Pro Pro Pro Thr Glu Gln Glu Leu Pro Pro Pr - #o Thr Glu Gln Glu Leu# 190- Pro Pro Pro Thr Glu Gln Glu Leu Pro Pro Pr - #o Thr Glu Gln Glu Leu# 205- Ala Pro Ser Thr Glu Gln Glu Leu Pro Pro Pr - #o Val Gly Glu Gly Gln# 220- Arg Leu Gln Val Pro Gly Glu His Gly Pro Gl - #n Gly Pro Pro Tyr Asp225 2 - #30 2 - #35 2 -#40- Asp Gln Gln Leu Leu Leu Glu Pro Thr Glu Gl - #u Gln Gln Glu Gly Pro# 255- Gln Glu Pro Leu Pro Pro Pro Pro Pro Pro Th - #r Arg Gly Glu Gln Pro# 270- Glu Gly Gln Gln Pro Gln Gly Pro Val Arg Gl - #n Asn Phe Phe Arg Arg# 285- Ala Leu Gly Ala Ala Arg Ser Arg Phe Gly Gl - #y Ala Arg Arg His Val# 300- Ser Gly Val Phe Arg Arg Val Arg Gly Gly Le - #u Asn Arg Ile Val Gly305 3 - #10 3 - #15 3 -#20- Gly Val Arg Ser Gly Phe Arg Arg Ala Arg Gl - #u Gly Val Val Gly Gly# 335- Val Arg Arg Leu Thr Ser Gly Ala Ser Leu Gl - #y Leu Gly Arg Val Gly# 350- Glu Gly Leu Gly Arg Ser Phe Tyr Arg Val Ar - #g Gly Ala Val Ser Ser# 365- Gly Arg Arg Arg Ala Ala Asp Gly Ala Ser As - #n Val Arg Glu Arg Phe# 380- Val Ala Ala Gly Gly Arg Val Arg Asp Ala Ph - #e Gly Ala Gly Leu Thr385 3 - #90 3 - #95 4 -#00- Arg Leu Arg Arg Arg Gly Arg Thr Asn Gly Gl - #u Glu Gly Arg Pro Leu# 415- Leu Gly Glu Gly Arg Glu Gln Asp Asp Gly Se - #r Gln# 425- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1909 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:- GCCACTGCTG TGTCTGAAGC GTGCCGATGT GTGCGCGTAC GCTTACAGAG AG - #CCTGCAAG 60- ACACTGGTTG GAAGACAAAA TTTTTCTTCT CAAGAGTTGA GCTTTAGTTT GG - #TCACTCGC 120- CGTTGGTTGT TCTGTGTGCT AGACGTACTC TAACGCAAAC CAGTCGAGGA AC - #ACACGAAC 180- GAGAGAGACG GCAATATCTC CCGTCGCGCT ATCATACCGG CAACATGGAT TG - #CGGACAGT 240- GCAGAAGGCA ACTGCACGCA GCAGGTGTTC TAGGCTTGTT TGTCACCCTT GC - #CACAGCAA 300- CCGTAGGATT GAGCCAAAGG GTGCCAGAGC TACCAGAAGT GGAGTCCTTT GA - #TGAAGTAG 360- GCACGGGAGC TCGACGGTCC GGGTCCATTG CGACCCTTCT TCCACAAGAC GC - #TGTTTTAT 420- ATGAGAACTC AGAGGACGTT GCCGTTCCGA GTGATTCAGC ATCGACCCCG TC - #ATACTTTC 480- ATGTGGAATC TCCAAGTGCT AGTGTGGAAG CCGCGACTGG CGCGGTGGGA GA - #GGTGGTGC 540- CGGACTGTGA AGAACGACAG GAACAGGGTG ACACGACGTT ATCCGATCAC GA - #TTTCCATT 600- CAGGTGGAAC TGAACAGGAG GGTTTGCCGG AAACAGAGGT GGCGCATCAG CA - #TGAGACAG 660- AAGAACAGTA CGGGACTGAA GGGATGCCCC CCCCTGTTCT GCCACCTGCA CC - #GGTAGTCC 720- ATCCGCGTTT TATTGCAGTA CCAGGGCCGT CGGTGCCTGT TCCATTTTTC AG - #TTTGCCAG 780- ACATCCACCC GGATCAGGTT GTGTATATTC TAAGGGTTCA GGGATCTGGG GA - #CTTCGACA 840- TCAGTTTCGA AGTTGGCCGA GCTGTGAAGC AGTTGGAAGC CATCAAGAAA GC - #ATACAGAG 900- AAGCCACCGG GAAGCTAGAA GCAGACGAGC TTGAGTCAGA AAGGGGACCT GC - #TGTTTCAC 960- CTCGACGAAG GCTGGTTGAC CTGATCAAAG ATAACCAGCG ACGACTCAGG GC - #GGCGCTTC1020- AGAAGATAAA GATACAGAAA AAGTTGGAGG AGATTGATGA CTTACTTCAG CT - #GACACGCG1080- CACTGAAGGC CATGGATGCC CGTCTGAGAG CCTGCCAGGA TATGGCACCG AT - #TGAGGAGG1140- CGCTGTGTCA CAAGACGAAG GCGTTTGGAG AAATGGTGTC CCAGAAAGCC AA - #GGAAATTC1200- GGGAGAAAGC GGCGTCCTTG TCTTCATTGT TAGGTGTCGA TGCTGTCGAA AA - #AGAATTGC1260- GGCGTGTCGA ACCGGAACAT GAAGATAACA CCAGAGTTGA AGCCAGGGTA GA - #GGAATTGC1320- AGAAGGCGCT GGAGAAGGCC GCGTCTGAGG CAAAGCAGCT CGTGGGGACC GC - #AGCAGGCG1380- AAATAGAGGA AGGAGTAAAA GCGGATACTC AGGCTGTGCA AGATAGCTCG AA - #AGACGTGT1440- TGACGAAGAG TCCAGTTGCG CTCGTGGAAG CCTTTAAAGC GATCCAGAGG GC - #TCTTCTTG1500- AGGCGAAGAC AAAGGAACTA GTAGAGCCTA CGTCTAAAGA AGCGGAGGAA GC - #TCGTCAGA1560- TCTTAGCGGA ACAGGCAGCT TGATTTCCCA AGGATGCAGT TAAAGATGGG GA - #TGCATGAT1620- AGGTAGCGCG CCCATTATCC CAATCCTTTA GCCGTCTACC GTGACGTGGA TC - #ATTATAGG1680- GGAAACAAGC ATTAGCAGAA TGATCGTGTA TCGCGGAACA CACGCATATC CG - #CACCAGTT1740- TTTCTAACGT ATGGTGAATG GGTTCAAGTC TGGGTTCAAG GCGCAGTGTC TA - #TGCAACAG1800- CGCCGGTTTC TGCCCTTCGT TTTTGCACAT GTGCACAGGT ATGTACAGTG TT - #TATGTATA1860# 1909TTCGT CAATGATGTA CAGAAAAAAA AAAAAAAAA- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 452 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:- Met Asp Cys Gly Gln Cys Arg Arg Gln Leu Hi - #s Ala Ala Gly Val Leu# 15- Gly Leu Phe Val Thr Leu Ala Thr Ala Thr Va - #l Gly Leu Ser Gln Arg# 30- Val Pro Glu Leu Pro Glu Val Glu Ser Phe As - #p Glu Val Gly Thr Gly# 45- Ala Arg Arg Ser Gly Ser Ile Ala Thr Leu Le - #u Pro Gln Asp Ala Val# 60- Leu Tyr Glu Asn Ser Glu Asp Val Ala Val Pr - #o Ser Asp Ser Ala Ser#80- Thr Pro Ser Tyr Phe His Val Glu Ser Pro Se - #r Ala Ser Val Glu Ala# 95- Ala Thr Gly Ala Val Gly Glu Val Val Pro As - #p Cys Glu Glu Arg Gln# 110- Glu Gln Gly Asp Thr Thr Leu Ser Asp His As - #p Phe His Ser Gly Gly# 125- Thr Glu Gln Glu Gly Leu Pro Glu Thr Glu Va - #l Ala His Gln His Glu# 140- Thr Glu Glu Gln Tyr Gly Thr Glu Gly Met Pr - #o Pro Pro Val Leu Pro145 1 - #50 1 - #55 1 -#60- Pro Ala Pro Val Val His Pro Arg Phe Ile Al - #a Val Pro Gly Pro Ser# 175- Val Pro Val Pro Phe Phe Ser Leu Pro Asp Il - #e His Pro Asp Gln Val# 190- Val Tyr Ile Leu Arg Val Gln Gly Ser Gly As - #p Phe Asp Ile Ser Phe# 205- Glu Val Gly Arg Ala Val Lys Gln Leu Glu Al - #a Ile Lys Lys Ala Tyr# 220- Arg Glu Ala Thr Gly Lys Leu Glu Ala Asp Gl - #u Leu Glu Ser Glu Arg225 2 - #30 2 - #35 2 -#40- Gly Pro Ala Val Ser Pro Arg Arg Arg Leu Va - #l Asp Leu Ile Lys Asp# 255- Asn Gln Arg Arg Leu Arg Ala Ala Leu Gln Ly - #s Ile Lys Ile Gln Lys# 270- Lys Leu Glu Glu Ile Asp Asp Leu Leu Gln Le - #u Thr Arg Ala Leu Lys# 285- Ala Met Asp Ala Arg Leu Arg Ala Cys Gln As - #p Met Ala Pro Ile Glu# 300- Glu Ala Leu Cys His Lys Thr Lys Ala Phe Gl - #y Glu Met Val Ser Gln305 3 - #10 3 - #15 3 -#20- Lys Ala Lys Glu Ile Arg Glu Lys Ala Ala Se - #r Leu Ser Ser Leu Leu# 335- Gly Val Asp Ala Val Glu Lys Glu Leu Arg Ar - #g Val Glu Pro Glu His# 350- Glu Asp Asn Thr Arg Val Glu Ala Arg Val Gl - #u Glu Leu Gln Lys Ala# 365- Leu Glu Lys Ala Ala Ser Glu Ala Lys Gln Le - #u Val Gly Thr Ala Ala# 380- Gly Glu Ile Glu Glu Gly Val Lys Ala Asp Th - #r Gln Ala Val Gln Asp385 3 - #90 3 - #95 4 -#00- Ser Ser Lys Asp Val Leu Thr Lys Ser Pro Va - #l Ala Leu Val Glu Ala# 415- Phe Lys Ala Ile Gln Arg Ala Leu Leu Glu Al - #a Lys Thr Lys Glu Leu# 430- Val Glu Pro Thr Ser Lys Glu Ala Glu Glu Al - #a Arg Gln Ile Leu Ala# 445- Glu Gln Ala Ala 450__________________________________________________________________________

Claims

1. A substantially purified protein comprising at least one amino acid sequence consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 16, 18, or 20 and immunogenic fragments thereof, or (b) an amino acid sequence encoded by a DNA sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 14, 15, 17 or 19.

2. An immunogenic composition which contains one or more proteins as claimed in claim 1.